

HOLOGIC INC
Form 10-Q
February 05, 2009
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 27, 2008

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 0-18281

Hologic, Inc.

(Exact name of registrant as specified in its charter)

Edgar Filing: HOLOGIC INC - Form 10-Q

Delaware
(State of incorporation)

04-2902449
(I.R.S. Employer Identification No.)

35 Crosby Drive, Bedford, Massachusetts
(Address of principal executive offices)

01730
(Zip Code)

(781) 999-7300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes No

As of February 3, 2009, 256,335,129 shares of the registrant's Common Stock, \$.01 par value, were outstanding.

Table of Contents

HOLOGIC, INC.

INDEX

	Page
PART I FINANCIAL INFORMATION	
Item 1. Financial Statements (unaudited)	
<u>Consolidated Balance Sheets as of December 27, 2008 and September 27, 2008</u>	3
<u>Consolidated Statements of Operations for the Three Months Ended December 27, 2008 and December 29, 2007</u>	4
<u>Consolidated Statements of Cash Flows for the Three Months Ended December 27, 2008 and December 29, 2007</u>	5
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	29
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	44
<u>Item 4. Controls and Procedures</u>	45
<u>PART II OTHER INFORMATION</u>	46
<u>SIGNATURES</u>	48
EXHIBITS	

Table of Contents

HOLOGIC, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except per share data)

	December 27, 2008	September 27, 2008
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 171,479	\$ 95,661
Restricted cash	3,146	3,629
Accounts receivable, less reserves of \$6,840 and \$6,532, respectively	318,536	327,201
Inventories, net (Note 5)	181,396	174,667
Deferred income tax assets, net	51,863	53,660
Income tax refundable		17,797
Prepaid expenses and other current assets	20,399	20,963
Total current assets	746,819	693,578
PROPERTY AND EQUIPMENT, net (Note 5)	280,982	283,975
OTHER ASSETS:		
Developed technology and know-how, net of accumulated amortization of \$150,294 and \$112,568, respectively	1,984,711	2,023,121
Customer relationship, net of accumulated amortization of \$32,602 and \$22,509, respectively	452,224	461,627
Other intangible assets, net of accumulated amortization of \$21,108 and \$18,407, respectively	142,263	144,903
Goodwill	4,455,108	4,450,496
Other, net	77,258	76,932
Total assets	\$ 8,139,365	\$ 8,134,632
LIABILITIES AND STOCKHOLDERS EQUITY		
CURRENT LIABILITIES:		
Current portion of long-term debt	\$ 36,836	\$ 38,480
Accounts payable	54,013	59,590
Accrued expenses (Note 5)	127,228	154,746
Deferred revenue	87,875	78,559
Deferred gain	9,500	9,500
Total current liabilities	315,452	340,875
Long-term debt, net of current portion (Note 6)	409,424	437,420
Convertible debt (Note 6)	1,725,000	1,725,000
Deferred income tax liabilities, net	924,950	920,838
Deferred service obligations long-term	9,939	10,777
Other long-term liabilities (Note 5)	58,003	57,453
Commitments and contingencies (Notes 6, 7, 8, 13, 15 and 16)		
STOCKHOLDERS EQUITY:		
Preferred stock, \$0.01 par value 1,623 shares authorized; 0 shares issued		
Common stock, \$0.01 par value 750,000 shares authorized; 256,457 and 256,373 shares issued, respectively	2,565	2,564

Edgar Filing: HOLOGIC INC - Form 10-Q

Capital in excess of par value	4,861,804	4,853,837
Retained deficit	(169,651)	(217,644)
Accumulated other comprehensive income	3,312	4,945
Treasury stock, at cost 214 shares	(1,433)	(1,433)
Total stockholders' equity	4,696,597	4,642,269
Total liabilities and stockholders' equity	\$ 8,139,365	\$ 8,134,632

See accompanying notes.

Table of Contents

HOLOGIC, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

	Three Months Ended	
	December 27, 2008	December 29, 2007
Revenues:		
Product sales	\$ 380,108	\$ 334,790
Service and other revenues	49,125	36,655
	429,233	371,445
Costs and expenses (1):		
Cost of product sales	123,715	149,077
Cost of product sales amortization of intangible assets	37,746	20,155
Cost of service and other revenues	37,107	34,378
Research and development	23,793	20,147
Selling and marketing	65,708	56,986
General and administrative	34,805	34,334
Amortization of acquired intangible assets	12,638	6,249
Impairment of acquired intangible assets (Note 19)		2,900
Acquired in-process research and development		370,000
	335,512	694,226
Income (loss) from operations	93,721	(322,781)
Interest income	446	2,253
Interest expense	(18,410)	(31,660)
Other expense, net	(3,081)	(15)
Income (loss) before income taxes	72,676	(352,203)
Provision for income taxes	24,683	6,405
Net income (loss)	\$ 47,993	\$ (358,608)
Net income (loss) per common and common equivalent share:		
Basic	\$ 0.19	\$ (1.65)
Diluted	\$ 0.19	\$ (1.65)
Weighted average number of common shares outstanding:		
Basic	256,212	216,882
Diluted	258,433	216,882

Edgar Filing: HOLOGIC INC - Form 10-Q

- (1) Stock-based compensation included in costs and expenses during the three months ended December 27, 2008 was \$644 for cost of revenues, \$1,325 for research and development, \$1,571 for selling and marketing and \$3,930 for general and administrative. Stock-based compensation included in costs and expenses during the three months ended December 29, 2007 was \$725 for cost of revenues, \$686 for research and development, \$715 for selling and marketing and \$5,457 for general and administrative.
See accompanying notes.

Table of Contents

HOLOGIC, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Three Months Ended	
	December 27, 2008	December 29, 2007
OPERATING ACTIVITIES		
Net income (loss)	\$ 47,993	\$ (358,608)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation	15,797	10,159
Amortization	50,384	26,404
Fair value write-up of Cytac and Third Wave inventory	584	41,500
Non-cash interest expense	2,843	5,653
Non-cash interest income	(70)	
Increase in unrecognized income tax benefits	1,200	572
Tax benefit related to exercise of non-qualified stock options	(78)	
Charge for in-process research and development		370,000
Charge for impairment of acquired intangible assets		2,900
Stock-based compensation expense	7,470	7,192
Deferred income taxes	715	(20,002)
Loss on disposal of property and equipment and intangible assets	231	57
Changes in assets and liabilities, net of acquisitions:		
Accounts receivable	5,262	(21,977)
Inventories	(8,707)	(10,767)
Income tax refundable	17,748	19,191
Prepaid expenses and other current assets	297	4,404
Accounts payable	(5,467)	(3,705)
Accrued expenses	(24,763)	(30,435)
Deferred revenue	9,448	7,764
Net cash provided by operating activities	120,887	50,302
INVESTING ACTIVITIES		
Merger with Cytac Corporation, net of cash acquired		(2,027,008)
Additional business acquisition consideration	(326)	
Decrease (increase) in restricted cash	483	(32,370)
Increase in other assets	(3,101)	(4,291)
Purchase of licensed technology and other intangible assets	(938)	
Purchase of property and equipment	(9,499)	(12,192)
Increase in equipment under customer usage agreements	(3,964)	(5,106)
Purchases of investment securities		(263)
Proceeds from sales and maturities of investment securities		2,638
(Decrease) increase in other liabilities	(164)	1,165
Net cash used in investing activities	(17,509)	(2,077,427)
FINANCING ACTIVITIES		
Proceeds from issuance of convertible notes, net of issuance costs		1,688,998
Proceeds under credit agreement, net of issuance costs		2,335,942

Edgar Filing: HOLOGIC INC - Form 10-Q

Financing costs on credit agreement	(283)	
Repayments under credit agreement	(29,042)	(2,055,353)
Payment upon conversion of Cytoc convertible notes		(38,334)
Increase in notes payable		2,055
Repayments of notes payable and capital leases	(290)	(290)
Tax benefit related to exercise of non-qualified stock options	78	
Net proceeds from sale of common stock pursuant to stock plans	668	148,829
Net cash (used in) provided by financing activities	(28,869)	2,081,847

Table of Contents

	Three Months Ended	
	December 27, 2008	December 29, 2007
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	1,309	(462)
NET INCREASE IN CASH AND CASH EQUIVALENTS	75,818	54,260
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	95,661	100,403
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 171,479	\$ 154,663
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:		
Issuance of common stock upon conversion of Cytoc convertible notes	\$	\$ 82,620

	Three Months Ended	
	December 27, 2008	December 29, 2007
BUSINESS ACQUISITION, NET OF CASH ACQUIRED:		
Fair value of tangible assets acquired	\$	\$ 531,100
Fair value of liabilities assumed		(261,200)
Fair value of stock issued		(3,671,400)
Fair value of options exchanged		(241,400)
Cost in excess of fair value of assets (Goodwill)		3,844,100
Fair value of acquired identifiable intangible assets		2,484,900
In-process research and development		370,000
Deferred tax liability		(937,500)
		2,118,600
Less cash and cash equivalents and investments acquired		85,400
Less acquisition costs paid prior to September 29, 2007		6,200
Net cash paid for acquisition	\$	\$ 2,027,000

See accompanying notes.

Table of Contents

HOLOGIC, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

(In thousands, except per share data)

(1) Basis of Presentation

The consolidated financial statements of Hologic, Inc. (the Company) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended September 27, 2008, included in the Company's Form 10-K as filed with the Securities and Exchange Commission on November 26, 2008.

The Consolidated Balance Sheet at September 27, 2008 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. The Consolidated Balance Sheet as of December 27, 2008, the Consolidated Statements of Operations and Consolidated Statements of Cash Flows for the three months ended December 27, 2008 and December 29, 2007 are unaudited but, in the opinion of management, include all adjustments (consisting of normal, recurring adjustments) necessary for a fair presentation of results for these interim periods.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management's estimates if past experience or other assumptions do not turn out to be substantially accurate. The results of operations for the three months ended December 27, 2008 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ended September 26, 2009.

Based on a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of the Company's market capitalization significantly below the book value of net assets, the Company concluded that potential goodwill impairment indicators existed as of December 27, 2008. As a result, the Company is performing an interim goodwill impairment analysis as of December 27, 2008. Please refer to Note 19 for further discussion.

During the fourth quarter of fiscal 2008, the Company determined that certain amounts previously classified as a component of Cost of Service and Other Revenues should be reclassified to Cost of Product Sales. The Company determined that the reclassification was not material to its consolidated financial statements and corrected the classification in the fourth quarter of fiscal 2008. These amounts totaled \$9,312 for the three months ended December 29, 2007, and have been reclassified to Cost of Product Sales to conform with the current period. Additionally, royalty expense previously recorded within Cost of Service and Other Revenues totaling \$388 for the three months ended December 29, 2007 has been reclassified to Cost of Product Sales to conform with the current period presentation.

On April 2, 2008, the Company effected a two-for-one stock split in the form of a stock dividend. The stock split has been retroactively reflected in the accompanying consolidated financial statements and notes for all periods presented.

(2) Fair Value Measurements

Effective September 28, 2008, the Company implemented Statement of Financial Accounting Standard (SFAS) No. 157, *Fair Value Measurement* (SFAS 157), for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In accordance with the provisions of FASB Staff Position (FSP) No. FAS 157-2, *Effective Date of FASB Statement No. 157*, the Company has elected to defer implementation of SFAS 157 as it relates to its non-financial assets and non-financial liabilities that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis until September 27, 2009. The Company is evaluating the impact, if any, this Standard will have on its non-financial assets and liabilities.

The adoption of SFAS 157 for financial assets and liabilities that are re-measured and reported at fair value at least annually did not have an impact on the Company's financial results.

Table of Contents

SFAS 157 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

Level 1 Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

Level 2 Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Level 3 Inputs to the valuation methodology are unobservable inputs based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of December 27, 2008, the Company's financial assets that are re-measured at fair value on a recurring basis consisted of \$37,107 in money market mutual funds that are classified as cash and cash equivalents in its Consolidated Balance Sheet, as there are no withdrawal restrictions, and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets.

The Company holds certain minority cost-method equity investments in non-publicly traded securities totaling \$9,278 at both December 27, 2008 and September 27, 2008, which are included in other long-term assets on the Company's Consolidated Balance Sheets. These investments are generally carried at cost as the Company owns less than 20% of the voting equity and does not have the ability to exercise significant influence over these companies. The Company regularly evaluates the carrying value of its investments. The Company's cost method investments are adjusted to fair value only when impairment charges are recorded for other-than-temporary declines in value and are determined using fair value criteria within the framework of SFAS 157. As the inputs utilized for the impairment assessment are not based on observable market data, these cost method investments are classified within Level 3 of the fair value hierarchy on a non-recurring basis. During fiscal 2008 and the three months ended December 27, 2008, none of the investments held were deemed to be in an other-than-temporary loss.

(3) Revenue Recognition

Upon the Company's release of its Dimensions product, the Company completed an evaluation of the software component of its Dimensions product in accordance with AICPA SOP 97-2, *Software Revenue Recognition* (SOP 97-2) and Emerging Issues Task Force (EITF) Issue No. 03-05, *Applicability of AICPA Statement of Position 97-2 to Non-Software Deliverables in an Arrangement Containing More-Than-Incidental Software* (EITF 03-05). The Company noted the following in its evaluation of the software component of its new Dimensions product:

Dimensions will be offered in different configurations offering different levels of functionality—two dimensional (2D) versus three dimensional (3D) imaging. Customers who purchase the 2D configuration will be able to upgrade the product to a 3D version and such upgrade will solely represent a software upgrade that will be marketed and sold separately. This differentiation from the Company's existing 2D digital mammography product is expected to be highlighted in the Company's marketing literature.

As part of the initial warranty of the Dimensions product, customers will receive not only bug fixes related to the software but also will receive any updates and enhancements to the software that are released. Therefore, the Company concluded that this represents Post Contract Support (PCS) as defined in SOP 97-2.

As a result, the Company has determined that the Dimensions product contains software that is more than incidental to the product as a whole and thus, will be accounted for under SOP 97-2. Therefore, the Company will recognize revenue upon installation and acceptance, if required, and will defer the vendor-specific objective evidence of fair value of the initial bundled PCS. The Company has determined that vendor-specific objective evidence of fair value of the initial bundled PCS exists based on the establishment of price for which this element will be sold separately by management having the relevant authority and that it is probable that this price will not change prior to when this service is sold separately. The Company has specified the renewal rates at which service can be purchased separately upon expiration of the initial PCS period and those rates are consistent.

Table of Contents**(4) Business Combinations****(a) Third Wave Technologies, Inc.**

On July 24, 2008 the Company completed its acquisition of Third Wave Technologies, Inc. (Third Wave) pursuant to a definitive agreement dated June 8, 2008. The Company has concluded that the acquisition of Third Wave does not represent a material business combination and therefore no pro-forma financial information has been provided herein. Subsequent to the acquisition date, the Company's results of operations include the results of Third Wave, which has been reported as a component of the Company's Diagnostics reporting segment.

Third Wave, located in Madison, Wisconsin, develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader chemistry. Third Wave's current clinical diagnostic offerings consist of products for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases. Third Wave recently submitted pre-market approval (PMA) applications for two human papillomavirus (HPV) tests to the U.S. Food and Drug Administration (FDA).

The Company paid \$11.25 per share of Third Wave, for an aggregate purchase price of approximately \$591,200 (subject to adjustment) consisting of approximately \$575,400 in cash in exchange for stock and warrants; approximately 668 of fully vested stock options granted to Third Wave employees in exchange for their vested Third Wave stock options, with an estimated fair value of approximately \$8,100; and approximately \$7,700 for acquisition related fees and expenses. There are no potential contingent consideration arrangements payable to the former shareholders in connection with this transaction. Additionally, the Company granted approximately 315 unvested stock options in exchange for unvested Third Wave stock options, with an estimated fair value of approximately \$5,100, which is being recognized as compensation expense over the vesting period.

The Company determined the fair value of the options issued in connection with the acquisition in accordance with EITF Issue No. 99-12, *Determination of the Measurement Date for the Market Price of Acquirer Securities Issued in a Purchase Business Combination* (EITF 99-12). The Company determined the measurement date to be July 24, 2008, the date the transaction was completed, as the number of shares to be issued according to the exchange ratio was not fixed until this date. The Company valued the securities based on the average market price for two days before the measurement date and the measurement date itself. The weighted average stock price was determined to be approximately \$23.54.

The preliminary purchase price is as follows:

Cash portion of consideration	\$ 575,400
Fair value of vested options exchanged	8,100
Direct acquisition costs	7,700
 Total estimated purchase price	 \$ 591,200

The fair value of vested Hologic common stock options exchanged for vested Third Wave options was included in the purchase price as such options were fully vested. The Company estimated the fair value of these stock options using the Binomial Option Pricing Model. The Company estimated the fair value of the stock options assuming no expected dividends and the following weighted-average assumptions:

Expected life	1.48 years
Expected volatility	42.16%
Risk-free interest rate	2.33%
Fair value per share determined in accordance with EITF 99-12	\$ 23.54

The allocation of the purchase price is based upon preliminary estimates of the fair value of assets acquired and liabilities assumed as of July 24, 2008. The Company is in the process of gathering information to finalize its valuation of certain assets and liabilities. The purchase price allocation is preliminary and will be finalized once the Company has all necessary information to complete its estimate, but generally no later than one year from the date of acquisition. The components and initial allocation of the purchase price consists of the following approximate amounts:

Edgar Filing: HOLOGIC INC - Form 10-Q

Net tangible assets acquired as of July 24, 2008	\$ 85,500
Increase in inventory to fair value	5,100
Increase in property and equipment to fair value	800
In-process research and development	195,200
Developed technology and know-how	92,300
Deferred income tax liability	(38,300)
Goodwill	250,600
Estimated Purchase Price	\$ 591,200

Table of Contents

The preliminary purchase price allocation resulted in goodwill of approximately \$241,800 as of July 24, 2008, the date of the acquisition. During the three months ended December 27, 2008, the Company increased goodwill in the amount of approximately \$8,800, primarily related to an \$11,400 reduction in the estimated net operating loss acquired, partially offset by a \$3,200 increase in the preliminary estimate of other tax attributes acquired.

Subsequent to the close of the Third Wave acquisition through December 27, 2008, stock options, originally issued by Third Wave and converted into options to purchase Hologic common stock, were exercised. The Company recorded the estimated tax benefit of approximately \$121 and \$368 related to the exercise of these options as a reduction to goodwill during fiscal 2009 and fiscal 2008, respectively.

Identifiable Intangible Assets

As part of the preliminary purchase price allocation, all intangible assets that were a part of the acquisition were identified and valued. It was determined that only developed technology had separately identifiable values. The fair value of the developed technology intangible assets was determined through the application of the income approach. Developed technology represents currently marketable purchased products that the Company continues to sell as well as utilize to enhance and incorporate into the Company's existing products.

Acquired In-Process Research and Development

As part of the preliminary purchase price allocation for Third Wave, approximately \$195,200 of the purchase price has been allocated to acquired in-process research and development projects. The amount allocated to acquired in-process research and development represents the estimated fair value based on risk-adjusted cash flows related to in-process projects utilizing a discount rate of 20% that have not yet reached technological feasibility and have no alternative future uses as of the date of the merger. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products. The fair value attributable to these in-process projects was expensed at the time of the acquisition. If the projects are not successful or completed in a timely manner, the Company may not realize the financial benefits expected for these projects or for the transaction as a whole.

The most significant acquired in-process technology related to the HPV Cervista High Risk (HR), for which the Company has estimated a value of approximately \$151,200. The Company currently sells HPV reagents that detect certain high risk HPV types as Analyte Specific Reagents (ASRs). In 2006, Third Wave began clinical trials for PMA submissions to the FDA for Cervista HR. The Company submitted the PMAs in April 2008. Subsequent to receiving FDA approval, management expects to discontinue selling the HPV ASRs and only sell HPV In Vitro Diagnostics (IVDs). As such, the HPV in-process research and development relates only to the HPV IVDs and the HPV ASRs were valued as developed technology. The estimated cost to complete this technology was approximately \$19,300.

The estimated cost to complete Third Wave's remaining in-process research and development projects in the aggregate was approximately \$9,800.

The net deferred income tax liability relates to the tax effect of acquired identifiable intangible assets and fair value adjustments to acquired inventory and property and equipment, as such amounts are not deductible for tax purposes.

(b) Cytoc Corporation

On October 22, 2007 the Company completed its merger with Cytoc Corporation (Cytoc) pursuant to the Agreement and Plan of Merger (Merger Agreement) entered into on May 20, 2007. Cytoc, headquartered in Marlborough, Massachusetts, is a diversified diagnostic and medical device company that designs, develops, manufactures, and markets innovative and clinically effective diagnostics and surgical products. Cytoc products cover a range of cancer and women's health applications, including cervical cancer screening, prenatal diagnostics, treatment of excessive menstrual bleeding and radiation treatment of early-stage breast cancer.

Upon the close of the merger, Cytoc shareholders received an aggregate of 132,038 shares of Hologic common stock and approximately \$2,094,800 in cash. In connection with the close of the merger, the Company entered into a credit agreement relating to a senior secured credit facility (the Credit Agreement) with Goldman Sachs Credit Partners L.P. and certain other lenders, in which the lenders committed to provide, in the aggregate, senior secured financing of up to approximately \$2,550,000 to pay for the cash portion of the merger consideration, for repayment of existing debt of Cytoc, for expenses relating to the merger and for working capital following the completion of the merger. As of the closing of the merger, the Company borrowed \$2,350,000 under this Credit Agreement.

The aggregate purchase price of approximately \$6,156,900 includes \$2,094,800 in cash; 132,038 shares of Hologic common stock at an estimated fair value of \$3,671,500; approximately 16,465 of fully vested stock options granted to Cytoc employees in exchange for their vested

Edgar Filing: HOLOGIC INC - Form 10-Q

Cytec stock options, with an estimated fair value of approximately \$241,400; the fair value of Cytec's outstanding convertible notes assumed in the merger of approximately \$125,000; and approximately \$24,200 of direct acquisition

Table of Contents

costs. There are no potential contingent consideration arrangements payable to the former Cytyc shareholders in connection with this transaction.

The Company has measured the fair value of the 132,038 shares of the Company common stock issued as consideration in connection with the merger under EITF 99-12. The Company determined the measurement date to be May 20, 2007, the date the transaction was announced, as the number of shares to be issued according to the exchange ratio was fixed without subsequent revision. The Company valued the securities based on the average market price a few days before and after the measurement date. The weighted average stock price was determined to be approximately \$27.81.

(i) Purchase price

The purchase price is as follows:

Cash portion of consideration	\$ 2,094,800
Fair value of securities issued	3,671,500
Fair value of vested options exchanged	241,400
Fair value of Cytyc's outstanding convertible notes	125,000
Direct acquisition costs	24,200
 Total estimated purchase price	 \$ 6,156,900

The fair value of vested Hologic common stock options exchanged for vested Cytyc options was included in the purchase price as such options were fully vested. The Company estimated the fair value of these stock options using the Binomial Option Pricing Model. The Company estimated the fair value of the stock options assuming no expected dividends and the following weighted-average assumptions:

Expected life	2.50 years
Expected volatility	35.10%
Risk-free interest rate	4.82%
Fair value per share determined in accordance with EITF 99-12	\$ 27.81

(ii) Purchase Price Allocation

The allocation of the purchase price is based upon estimates of the fair value of assets acquired and liabilities assumed as of October 22, 2007. As a result of the merger, the Company has assumed Cytyc's obligation to Adiana's former stockholders to make contingent earn-out payments based on the achievement of milestones. The Company has considered the provision of EITF Issue No. 95-8, *Accounting for Contingent Consideration Paid to the Shareholders of an Acquired Enterprise in a Purchase Business Combination*, and concluded that this contingent consideration will represent additional purchase price. As a result, goodwill will be increased by the amount of the additional consideration, if any, when it becomes due and payable. As of December 27, 2008, the Company has not recorded any amounts for the potential earn-outs. The Company had formulated and undertaken a plan to restructure certain of Cytyc's activities. The Company recorded a liability of approximately \$2,800 in accordance with EITF Issue No. 95-3, *Recognition of Liabilities in Connection with a Purchase Business Combination* (EITF 95-3), primarily related to the termination of certain employees, minimum inventory purchase commitments and other contractual obligations for which the related business activities have been discontinued.

Book value of net assets acquired as of October 22, 2007	\$ 1,158,600
Less: write-off of existing deferred financing costs, goodwill and intangible assets, including related deferred taxes	(787,900)
 Adjusted book value of assets acquired	 370,700
Remaining allocation:	
Increase inventory to fair value	42,300
Increase property and equipment to fair value	5,100

Edgar Filing: HOLOGIC INC - Form 10-Q

Increase in liabilities recorded in accordance with EITF 95-3	(2,800)
Decrease deferred revenue to fair value	400
Identifiable intangible assets at fair value	2,486,600
Acquired in-process research and development	370,000
Deferred taxes	(943,400)
Goodwill	3,828,000
Total purchase price	\$ 6,156,900

Table of Contents**(iii) Valuation of Intangible Assets and Goodwill**

The purchase price for the merger with Cytyc has been allocated to assets acquired and liabilities assumed based on management's estimate of their fair values. Management has allocated the purchase price in excess of net tangible assets acquired to identifiable intangible assets and in-process research and development based upon a detailed valuation that relies on information and assumptions further described below. Any excess purchase price over the fair value of the net tangible and intangible assets acquired and liabilities assumed is allocated to goodwill.

Identifiable Intangible Assets

As part of the preliminary purchase price allocation, the Company determined that Cytyc's identifiable intangible assets include existing technology, customer relationships and trade names. Cytyc's existing technology relates to patents, patent applications and know-how with respect to the technologies embedded in its currently marketed products. In determining the allocation of the purchase price to existing technology, consideration was only given to patents and patent applications that relate to products that have been approved by the FDA. Cytyc's customer relationship assets relate to relationships that Cytyc's sales force has developed with obstetricians/gynecologists and gynecological surgeons, breast surgeons, radiation oncologists, clinical laboratories and other physicians. The trade names relate to both the Cytyc name as well as key product names.

The Company used the income approach to value the existing technology and marketing based intangibles. This approach calculates fair value by discounting the after-tax cash flows back to a present value. The baseline data for this analysis was the cash flow estimates used to price the transaction. Cash flows were forecasted for each intangible asset, then discounted based on an appropriate discount rate. The discount rates applied, which ranged between 10.5% and 13.5%, were benchmarked with reference to the implied rate of return from the transaction model as well as Cytyc's weighted average cost of capital based on the capital asset pricing model.

In estimating the useful life of the acquired assets, the Company considered paragraph 11 of SFAS No. 142, *Goodwill and Other Intangible Assets*, which lists the pertinent factors to be considered when estimating the useful life of an intangible asset. These factors included a review of the expected use by the combined company of the assets acquired, the expected useful life of another asset (or group of assets) related to the acquired assets, legal, regulatory or other contractual provisions that may limit the useful life of an acquired asset or may enable the extension of the useful life of an acquired asset without substantial cost, the effects of obsolescence, demand, competition and other economic factors, and the level of maintenance expenditures required to obtain the expected future cash flows from the asset. The Company is amortizing these intangible assets over their estimated useful lives using a method that is based on estimated future cash flows as the Company believes this will approximate the pattern in which the economic benefits of the assets will be utilized.

Acquired In-Process Research and Development

As part of the preliminary purchase price allocation for Cytyc, approximately \$370,000 of the purchase price has been allocated to acquired in-process research and development projects. The amount allocated to acquired in-process research and development represents the estimated fair value based on risk-adjusted cash flows related to in-process projects that have not yet reached technological feasibility and have no alternative future uses as of the date of the merger. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products. The fair value attributable to these in-process projects was expensed at the time of the merger. If the projects are not successful or completed in a timely manner, the Company may not realize the financial benefits expected for these projects or for the transaction as a whole.

The fair value assigned to acquired in-process research and development was determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting net cash flows from the projects, and discounting the net cash flows to their present value. The revenue projections used to value the acquired in-process research and development were based on estimates of relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by the Company and its competitors. The resulting net cash flows from such projects were based on management's estimates of cost of sales, operating expenses, and income taxes from such projects.

The rates utilized to discount the net cash flows to their present value of 12.5% to 13.5% were based on estimated cost of capital calculations and the implied rate of return from the transaction model plus a risk premium. Due to the nature of the forecasts and the risks associated with the developmental projects, appropriate risk-adjusted discount rates were used for the in-process research and development projects. The discount rates are based on the stage of completion and uncertainties surrounding the successful development of the purchased in-process technology projects.

Edgar Filing: HOLOGIC INC - Form 10-Q

The acquired in-process research and development of Cytoc related to the following research and development projects: Adiana Complete TransCervical Sterilization (TCS) System and expanded labeling of the NovaSure System, Gestiva, the ThinPrep Imaging System, the ThinPrep Processor and the Helica Thermal Coagulator System (Helica).

The most significant acquired in-process technology related to the Adiana Complete TCS System for which the Company has estimated a value of approximately \$220,000. The TCS product is an incisionless trans-cervical permanent sterilization device

Table of Contents

intended to be performed as an office-based procedure. The system consists of three different parts: a disposable applicator, an implantable polymer matrix and a radio frequency controller. The procedure can be performed in a hospital or physician's office, and should generally take twelve minutes, with a thirty to forty minute recovery time. As of December 27, 2008 the estimated remaining costs to complete the clinical trials were expected to be approximately \$400.

Cytac's other in-process research and development projects were at different stages of development, ranging from the early stages of development to Phase IIb prototype building, ongoing clinical trials and submission to the FDA of PMA and drug applications. FDA approval or clearance had not been granted for any of the products classified as in-process research and development, nor had Cytac received any foreign approvals or clearances for any of these products. All products classified as in-process research and development require various levels of in-house and external testing, clinical trials and approvals from the FDA before these future products could be marketed. The estimated cash requirements in the aggregate to complete these remaining products were expected to be approximately \$5,700. Certain of these projects that have been discontinued or delayed are not included in this estimate as their cost to complete and timing of completion are unknown at this time. Certain of the projects included in this estimated cash requirement have been delayed to fiscal 2010 and the estimated costs for these projects have been increased accordingly.

The successful development of new products and product enhancements is subject to numerous risks and uncertainties, both known and unknown, including, unanticipated delays, access to capital, budget overruns, technical problems and other difficulties that could result in the abandonment or substantial change in the design, development and commercialization of these new products and enhancements including, for example, changes requested by the FDA in connection with PMA applications for products or 510(k) notification. Given the uncertainties inherent with product development and introduction, there can be no assurance that any of the Company's product development efforts will be successful on a timely basis or within budget, if at all. The failure of the Company to develop new products and product enhancements on a timely basis or within budget could harm the Company's results of operations and financial condition.

Goodwill

The preliminary purchase price allocation resulted in goodwill of approximately \$3,844,100 as of October 22, 2007, the date of the merger. During the three months ended December 27, 2008, the Company reduced goodwill related to the Cytac merger in the amount of approximately \$1,900 primarily related to a decrease in the valuation allowance related to certain tax assets acquired where the Company has determined that it is more likely than not that these assets will be realized. The Company also reduced this goodwill in the amount of approximately \$14,200 from the date of acquisition through September 27, 2008. The reduction was primarily related to a \$16,800 increase in the preliminary valuation of assets acquired (primarily related to deferred tax assets acquired), an \$1,845 increase in the preliminary valuation of certain tangible assets and a \$1,700 increase in the preliminary valuation of certain intangible assets which were partially offset by a \$5,900 increase in the preliminary estimate of liabilities assumed (primarily related to current tax liabilities) and a \$200 increase in the preliminary estimate of acquisition costs and expenses.

The factors contributing to the recognition of this amount of goodwill are based upon several strategic and synergistic benefits that are expected to be realized from the combination. These benefits include the expectation that the Company's complementary products and technologies will create a leading women's healthcare company with an enhanced presence in hospitals, private practices and healthcare organizations. The Company also expects to realize substantial synergies through the use of Cytac's OB/GYN and breast surgeon sales channel to cross-sell the Company's existing and future products. The merger provides the Company broader channel coverage within the United States and expanded geographic reach internationally, as well as increased scale and scope for further expanding operations through product development and complementary strategic transactions.

Subsequent to the close of the Cytac merger through December 27, 2008, vested stock options, originally issued by Cytac and converted into options to purchase Hologic common stock, were exercised. The Company recorded the estimated tax benefit of approximately \$49,300 related to the exercise of these options as a reduction to goodwill during fiscal 2008.

Goodwill as of December 27, 2008 related to the Cytac merger was approximately \$3,778,700.

Table of Contents**Supplemental Pro-forma Information**

The following unaudited pro-forma information presents the consolidated results of operations of the Company and Cytyc as if the transaction had occurred at the beginning of each period presented, with pro-forma adjustments to give effect to amortization of intangible assets, an increase in interest expense on acquisition financing, subsequent refinancing and certain other adjustments together with related tax effects:

(approximate amounts in thousands, except per share data)	December 29, 2007
Net revenue	\$ 408,351
Net income	\$ 41,298
Net income per common share:	
Basic	\$ 0.17
Diluted	\$ 0.16

The \$370,000 charge for acquired in-process research and development, the fair value of the inventory step-up of \$41,500, stock-based compensation of \$60,000, direct acquisition fees and expenses of \$28,000 and change of control payments of \$18,600 that were a direct result of the transaction are excluded from the unaudited pro-forma information above. The unaudited pro-forma results are not necessarily indicative of the results that the Company would have attained had the merger with Cytyc occurred at the beginning of the periods presented.

Prior to the close of the merger, the Board of Directors of Cytyc approved a modification to certain outstanding equity awards for Cytyc employees, which was consented to by Hologic. The modification provided for the acceleration of vesting upon the close of the merger for those awards that did not provide for acceleration upon a change of control as part of the original terms of the award. This modification was consented to by the Company so that the Company would not incur stock-based compensation charges that it otherwise would have if the awards had continued to vest under their original terms.

(5) Other Balance Sheet Information

Components of selected captions in the Consolidated Balance Sheets at December 27, 2008 and September 27, 2008 consisted of:

	December 27, 2008	September 27, 2008
Inventories, net		
Raw material and work-in-process	\$ 109,316	\$ 106,291
Finished goods	72,080	68,376
	\$ 181,396	\$ 174,667

Inventories are stated at the lower of cost (first-in, first-out) or market.

Certain work-in-process and finished goods inventories consist of material, labor and manufacturing overhead.

	December 27, 2008	September 27, 2008
Property and Equipment, net		
Equipment and software	\$ 179,045	\$ 172,790
Customer usage equipment	103,069	100,315
Building and improvements	56,120	55,743
Leasehold improvements	39,030	38,620

Edgar Filing: HOLOGIC INC - Form 10-Q

Furniture and fixtures	11,127	11,083
Land	8,931	8,978
	397,322	387,529
Less accumulated depreciation and amortization	(116,340)	(103,554)
	\$ 280,982	\$ 283,975
Accrued Expenses		
Accrued compensation and employee benefits	\$ 52,058	\$ 69,882
Accrued commissions	12,970	15,768
Accrued warranty, current portion	8,084	9,080
Accrued income and other taxes	13,683	11,744
Accrued interest	4,566	11,284
Other accrued expenses	35,867	36,988
	\$ 127,228	\$ 154,746

Table of Contents

	December 27, 2008	September 27, 2008
Other Long-Term Liabilities		
Accrued lease obligation long-term	\$ 31,319	\$ 31,204
Reserve for income tax uncertainties	13,684	12,307
Pension liabilities long-term	6,764	6,995
Other	6,236	6,947
	\$ 58,003	\$ 57,453

Restricted Cash

Restricted cash is primarily comprised of bank deposits to fund deferred compensation payments to former executives. The Company expects to make all payments within fiscal 2009.

(6) Indebtedness(a) Credit Agreement

In connection with its acquisition of Third Wave, on July 17, 2008, the Company entered into an amended and restated credit agreement (the Amended Credit Agreement) with Goldman Sachs Credit Partners L.P. and certain other lenders (collectively, the Lenders). The Amended Credit Agreement amended and restated the Company's existing credit agreement with the Lenders, dated as of October 22, 2007.

Pursuant to the terms and conditions of the Amended Credit Agreement, the Lenders committed to provide senior secured financing in an aggregate amount of up to \$800,000. The credit facility consisted of a \$400,000 senior secured tranche A term loan (Term Loan A); a \$200,000 senior secured tranche B term loan (Term Loan B); and a \$200,000 senior secured revolving credit facility (the Revolving Facility).

In order to complete the acquisition of Third Wave, the Company borrowed \$540,000 under the credit facilities on July 17, 2008, consisting of \$400,000 under the Term Loan A and \$140,000 under the Term Loan B. As of December 27, 2008, the Company had an aggregate of approximately \$436,000 of principal outstanding under this credit facility of which approximately \$321,000 was under the Term Loan A and approximately \$115,000 was under the Term Loan B. The long-term portion of the Term Loan A and Term Loan B loans were approximately \$288,000 and \$113,000, respectively, at December 27, 2008. The Company had no amounts outstanding and no scheduled required payments under its Revolving Facility and, therefore, had full availability of the \$200,000 Revolving Facility as of December 27, 2008. The final maturity dates for the credit facility are September 30, 2012 for the Term Loan A and Revolving Facility and March 31, 2013 for the Term Loan B.

The domestic subsidiaries of the Company which are party to the Amended Credit Agreement (including Third Wave, which joined as a party to the Amended Credit Agreement on July 24, 2008) have guaranteed the Company's obligations under the credit facilities and the credit facilities are secured by first-priority liens on, and first-priority security interests in, substantially all of the assets of the Company and all subsidiaries party to the Amended Credit Agreement, a first priority security interest in 100% of the capital stock issued by each guarantor, 65% of the capital stock issued by certain first-tier foreign subsidiaries of the Company and all intercompany debt. The security interests are evidenced by an Amended and Restated Pledge and Security Agreement by and among Goldman Sachs Credit Partners L.P., as collateral agent, Hologic and the other parties therein named (the Amended Pledge and Security Agreement). The Amended Pledge and Security Agreement amended and restated Hologic's existing Pledge and Security Agreement by and among Goldman Sachs Credit Partners L.P., as collateral agent, Hologic and the other parties therein named, dated as of October 22, 2007.

All amounts outstanding under the amended credit facilities will bear interest, at Hologic's option, as follows:

Initially, with respect to loans made under the Revolving Facility and the Term Loan A facility:

- (i) at the Base Rate plus 1.50% per annum; or
- (ii) at the reserve adjusted Eurodollar Rate plus 2.50% per annum; and

Edgar Filing: HOLOGIC INC - Form 10-Q

With respect to loans made under the Term Loan B facility:

(i) at the Base Rate plus 2.25% per annum; or

(ii) at the reserve adjusted Eurodollar Rate plus 3.25% per annum.

The margin applicable to loans under the Revolving Facility and the Term Loan A is subject to specified changes based on certain changes in the leverage ratio as specified in the Amended Credit Agreement.

Interest accruing at the base rate generally is payable by the Company on a quarterly basis. Interest accruing at the Eurodollar Rate is payable on the last day of selected interest periods (which shall be one, two, three and six months and in certain circumstances,

Table of Contents

nine or twelve months) unless the interest period exceeds three months, in which case, interest will be due at the end of every three months.

Borrowings outstanding under the Amended Credit Agreement during the three months ended December 27, 2008 had a weighted average interest rate of 5.24%. At December 27, 2008 the interest rates on the outstanding Term Loan A borrowings ranged from 4.0% to 4.75% and on the Term Loan B borrowings ranged from 4.75% to 5.25%. Interest expense under the Amended Credit agreement for the term loans totaled \$6,793 during the first quarter of fiscal 2009, which included non-cash interest expense of approximately \$1,099 related to the amortization of the capitalized deferred financing costs related to this facility. As of December 27, 2008, there was \$16,033 in deferred financing costs related to the Term Loans classified as Other Assets on the Company's Consolidated Balance Sheet.

Interest expense under the Amended Credit Agreement for the Revolving Facility totaled \$487 during the first quarter of fiscal 2009, consisting of non-cash interest expense of \$243 related to the amortization of capitalized deferred financing costs as well as commitment fees on the unused portion of this facility. As of December 27, 2008, there was \$3,712 in deferred financing costs related to the Revolving Facility classified as Other Assets on the Company's Consolidated Balance Sheet.

Borrowings under the original credit agreement from initial drawdown at October 22, 2007 through December 29, 2007 had a weighted average interest rate of 6.97%. Interest expense under these credit facilities totaled \$28,400 during the three months ended December 29, 2007, which included non-cash interest expense of approximately \$5,020 related to the amortization of the capitalized deferred financing costs.

The Company will pay a quarterly commitment fee, at a per annum rate of 0.50%, on the undrawn commitments available under the Revolving Facility, which per annum rate is subject to reduction based on a leverage ratio as specified in the Amended Credit Agreement.

The credit facilities contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including financial covenants which require the Company to maintain maximum leverage and minimum interest coverage ratios, as of the last day of each fiscal quarter. The Company was in compliance with all covenants as of December 27, 2008.

(b) Convertible Notes

On December 10, 2007, the Company issued and sold \$1,725,000 aggregate original principal amount of 2.00% Convertible Senior Notes due 2037 (the "Convertible Notes"). The Convertible Notes were registered under an effective Registration Statement and were issued pursuant to an Indenture between the Company and Wilmington Trust Company, as Trustee (the "Indenture") and a First Supplemental Indenture thereto (the "Supplemental Indenture"), both dated December 10, 2007.

Holders may require the Company to repurchase the Convertible Notes on December 13 of 2013, and each of December 15, 2017, 2022, 2027 and 2032 at a repurchase price equal to 100% of their accreted principal amount, plus accrued and unpaid interest. The Company may redeem any of the Convertible Notes beginning December 18, 2013, by giving holders at least 30 days' notice. The Company may redeem the Convertible Notes either in whole or in part at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest, including contingent interest and liquidated damages, if any, to, but excluding, the redemption date.

Interest expense under the Convertible Notes totaled \$10,222 and \$2,093 during the three months ended December 27, 2008 and December 29, 2007, respectively, which included non-cash interest expense of \$1,501 and \$271, respectively, related to the amortization of the capitalized deferred financing costs related to the Convertible Notes Agreement. As of December 27, 2008, there was \$29,750 in deferred financing costs related to the Convertible Notes classified as Other Assets on the Company's Consolidated Balance Sheet.

The Convertible Notes bear interest at a rate of 2.00% per year on the principal amount, payable semi-annually in arrears in cash on June 15 and December 15 of each year, beginning June 15, 2008 and ending on December 15, 2013. The Convertible Notes will accrete principal from December 15, 2013 at a rate that provides holders with an aggregate annual yield to maturity of 2.00% per year. Beginning with the six month interest period commencing December 15, 2013, the Company will pay contingent interest during any six month interest period to the holders of Convertible Notes if the trading price, as defined, of the Convertible Notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the Convertible Notes.

The holders of the Convertible Notes may convert the notes into shares of the Company's common stock at a conversion price of approximately \$38.60 per share, subject to adjustment, prior to the close of business on September 15, 2037, subject to prior redemption or repurchase of the notes, upon the occurrence of certain events, as defined. None of the events that would allow the holders to convert prior to September 15, 2037 have occurred to date.

Edgar Filing: HOLOGIC INC - Form 10-Q

In lieu of delivery of shares of the Company's common stock in satisfaction of the Company's obligation upon conversion of the Convertible Notes, the Company may elect to deliver cash or a combination of cash and shares of the Company's common stock. If the Company elects to satisfy its conversion obligation in a combination of cash and shares of the Company's common stock, the Company will deliver up to a specified dollar amount of cash per \$1,000 original principal amount of Convertible Notes, and will settle the remainder of the conversion obligation in shares of its common stock, in each case as provided in the Indenture. It is the

Table of Contents

Company's current intent and policy to settle any conversion of the Convertible Notes as if the Company had elected to make the net share settlement election.

The Convertible Notes are the Company's senior unsecured obligations and rank equally with all of the Company's existing and future senior unsecured debt and prior to all future subordinated debt. The Convertible Notes are effectively subordinated to any future secured indebtedness to the extent of the collateral securing such indebtedness, and structurally subordinated to all indebtedness and other liabilities (including trade payables) of the Company's subsidiaries.

If an event of default, as defined, relates to the Company's failure to comply with the reporting obligations in the Convertible Notes, if the Company so elects, the sole remedy of the holders of the Convertible Notes for the first 90 days following such event of default consists exclusively of the right to receive an extension fee on the notes in an amount equal to 0.25% of the accreted principal amount of the Convertible Notes.

Based on the Company's evaluation of the Convertible Notes in accordance with EITF Issue No. 00-19, *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock*, and SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities* (SFAS 133), the Company determined that the Convertible Notes contained a single embedded derivative, comprising both the contingent interest feature and the filing failure penalty payment requiring bifurcation as the features were not clearly and closely related to the host instrument. The Company has determined that the value of this embedded derivative was nominal as of December 10, 2007 and December 27, 2008.

As of December 27, 2008, upon conversion, including the potential premium that could be payable on a fundamental change (as defined), the Company would issue a maximum of approximately 56,000 common shares to the Convertible Note holders.

Please See Note 20, *Recent Accounting Pronouncements*, for a discussion related to the impact of the adoption of FASB Staff Position Accounting Principles Board (APB) 14-1, *Accounting for Convertible Debt Instruments that May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)* in fiscal 2010.

(c) AEG Debt

The Company's AEG subsidiary has approximately \$10,000 outstanding at December 27, 2008 under certain debt agreements. The terms of the agreements have various maturities ranging from December 30, 2010 through March 30, 2014. Outstanding borrowings had interest rates ranging from 3.9% to 4.3% and 5.6% to 7.2% during the three months ended December 27, 2008 and December 29, 2007, respectively. Interest expense incurred under these debt agreements totaled \$145 and \$191 during the three months ended December 27, 2008 and December 29, 2007, respectively.

(7) Commitments and Contingencies

(a) Contingent Earn-Out Payments

As a result of the Cytoc merger, the Company assumed the obligation to the former Adiana stockholders to make contingent earn-out payments tied to the achievement of milestones. The milestone payments include potential contingent payments of up to \$155,000, based on the achievement of certain FDA milestones and on incremental sales growth of the Adiana permanent contraception product during the four-year period following FDA approval of this product.

The Company satisfied its obligation for a second and final earn-out to the former Suros Surgical Systems, Inc. (Suros) stockholders related to Suros' incremental revenue growth for revenues earned through July 31, 2008. The Company accrued an amount of approximately \$24,500 for this second annual earn-out in the fourth quarter of 2008, with an increase to goodwill, which was paid in full as of December 27, 2008. The Company had also made a payment of approximately \$19,000 to the former Suros stockholders in the fourth quarter of fiscal 2007 for the first year earn-out.

The Company also has an obligation for up to two annual earn-out payments not to exceed \$15,000 in the aggregate based on BioLucent's achievement of certain revenue targets. The Company has considered the provision of EITF Issue No. 95-8, *Accounting for Contingent Consideration Paid to the Shareholders of an Acquired Enterprise in a Purchase Business Combination*, and concluded that this contingent consideration will represent additional purchase price. As a result, goodwill will be increased by the amount of the additional consideration, if any, when it becomes due and payable. As of December 27, 2008, the revenue targets have not been achieved and the Company has not recorded any amounts for these potential earn-outs.

(b) Purchase Obligations

In September 2005, the Company entered into an exclusive distribution and service agreement in the United States under which the Company will sell and service a line of extremity MRI systems. On October 31, 2007 the Company and Esaote amended the terms of this agreement such that the Company's remaining minimum purchase obligation is approximately \$3,000 through December 31, 2008. The Company has accrued this obligation as of December 27, 2008.

Table of Contents**(8) Pension and Other Employee Benefits**

In conjunction with its acquisition of AEG, the Company assumed certain defined benefit pension plans covering the employees of the AEG German subsidiary (the Pension Benefits). As of September 29, 2007 the Company adopted SFAS No. 158, *Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106 and 132(R)* (SFAS 158), using a prospective approach. The adoption of SFAS 158 did not impact the Company's compliance with its debt covenants under its credit agreements, cash position or results of operations.

As of December 27, 2008 and September 27, 2008, the Company has recorded a pension liability of approximately \$7,080 and \$7,323, respectively, primarily as a component of long-term liabilities, in the accompanying consolidated financial statements. As of December 27, 2008 and September 27, 2008, the pension plans held no assets. Under German law, there are no rules governing investment or statutory supervision of the pension plan. As such, there is no minimum funding requirement imposed on employers. Pension benefits are safeguarded by the Pension Guaranty Fund; a form of compulsory reinsurance that guarantees an employee will receive vested pension benefits in the event of insolvency. The Company's net periodic benefit cost and components thereof were not material during the three months ended December 27, 2008 and December 29, 2007.

(9) Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units and convertible debt.

The Company applies the provisions of EITF No. 04-08, *The Effect of Contingently Convertible Instruments on Diluted Earnings per Share* to determine diluted weighted average shares outstanding as it relates to its outstanding convertible notes and the remaining Cytoc Notes. Accordingly, the Company uses the treasury stock method to determine dilutive weighted average shares related to its convertible notes and the if-converted method as it relates to the remaining Cytoc Notes.

A reconciliation of basic and diluted share amounts are as follows:

	Three months ended	
	December 27, 2008	December 29, 2007
Numerator:		
Net income (loss), as reported, for basic earnings per share	\$ 47,993	\$ (358,608)
Interest expense on Cytoc Notes, net of tax	1	
Net income (loss), as adjusted, for diluted earnings per share	\$ 47,994	\$ (358,608)
Denominator:		
Basic weighted average common shares outstanding	256,212	216,882
Weighted average common equivalent shares from assumed exercise of stock options, restricted stock units and stock purchase plan	2,211	
Weighted average common equivalent shares from assumed conversion of convertible notes	10	
Diluted weighted average common shares outstanding	258,433	216,882
Basic net income (loss) per common share	\$ 0.19	\$ (1.65)
Diluted net income (loss) per common share	\$ 0.19	\$ (1.65)

Diluted weighted average shares outstanding do not include options outstanding to purchase 11,064 common shares and 2,060 outstanding restricted stock units for the three months ended December 27, 2008, as their effect would have been anti-dilutive. Diluted weighted average

Edgar Filing: HOLOGIC INC - Form 10-Q

shares outstanding do not include options outstanding to purchase 5,720 common shares and 232 outstanding restricted stock units for the three months ended December 29, 2007, as their effect would have been anti-dilutive. Diluted weighted average shares outstanding for the three months ended December 29, 2007 do not include 129 common shares that would be issued upon conversion of the Cytoc notes, as their effect would have been anti-dilutive. Diluted average shares outstanding do not include any effect resulting from the conversion of the Company's convertible notes as their impact would be anti-dilutive for all periods presented.

Table of Contents**(10) Stock-based Compensation**

Share-based compensation expense in the three months ended December 27, 2008 and December 29, 2007 is as follows:

	Three months ended	
	December 27, 2008	December 29, 2007
Cost of Product Sales	\$ 644	\$ 725
Research and Development	1,325	686
Selling and Marketing	1,571	715
General and Administrative	3,930	5,457

Stock Options

The Company granted approximately 2,814 and 1,360 stock options, respectively, during the three months ended December 27, 2008 and December 29, 2007 with exercise prices ranging from \$13.07 to \$14.50 and a weighted average exercise price of \$14.50 in the first quarter of fiscal 2009 and from \$8.23 to \$34.91 and a weighted average exercise price of \$27.32 in the first quarter of fiscal 2008. There were 17,083 options outstanding at December 27, 2008 with a weighted average exercise price of \$16.79.

The Company has elected to use a binomial model to determine the weighted average fair value of options. The weighted-average assumptions utilized to value these options are indicated in the following table:

	Three months ended	
	December 27, 2008	December 29, 2007
Risk-free interest rate	2.0%	4.0%
Expected volatility	46%	37-38%
Expected life (in years)	4.0	4.0-4.6
Dividend yield		
Forfeiture rate	7.74%	9.0%
Weighted average fair value of options granted	\$ 5.43	\$ 10.97

Included in stock-based compensation expense for the three months ended December 29, 2007 was \$2,662 as a result of the acceleration of vesting for certain outstanding Hologic stock options upon the close of the merger with Cytoc. The original terms of these employee stock options provided for acceleration of vesting upon a change of control.

Also included in stock-based compensation during the three months ended December 29, 2007 was \$2,264 as a result of a modification of certain stock options in connection with the Cytoc Merger Agreement in May 2007. The modification provided for acceleration of vesting of the unvested options upon a termination as a result of a change of control, as well as an extension of the period to exercise vested options from 90 days to December 31, 2009, which occurred upon the close of the merger with Cytoc.

Restricted Stock Units

The Company granted approximately 1,629 and 122 restricted stock units, respectively, during the three months ended December 27, 2008 and December 29, 2007 with weighted average grant date fair values of \$14.50 in the first quarter of fiscal 2009 and \$32.82 in the first quarter of fiscal 2008. As of December 27, 2008, there were 3,069 unvested restricted stock units outstanding with a weighted average grant date fair value of \$22.22.

The estimated forfeiture rate for restricted stock awards used in determining the expense recorded in the Company's Consolidated Statements of Operations was 6.4% for the three month period ended December 27, 2008.

Stock-based compensation expense for the three months ended December 27, 2008 and December 29, 2007 for restricted stock units included \$41 and \$570, respectively, as a result of the acceleration of vesting for certain outstanding restricted stock units in connection with the acquisition of Third Wave and the merger with Cytoc. The original terms of these restricted stock units provided for acceleration of vesting upon

a change of control.

Employee Stock Purchase Plans

At the Company's March 11, 2008 Annual Meeting of Stockholders, the Company's 2008 Employee Stock Purchase Plan (the "ESP Plan") was approved. The plan meets the criteria set forth in SFAS 123(R)'s definition of a non-compensatory plan and will, therefore, not give rise to recognizable compensation expense. Employees who have completed three consecutive months, or two years, whether or not consecutive, of employment with the Company or any of its participating subsidiaries are eligible to participate

Table of Contents

in the ESP Plan. The ESP Plan allows participants to purchase common stock of the Company at 95% of the fair market value, as defined. A total of 400 shares may be issued under the ESP Plan; however no shares have been issued to date.

Option Exchange Program

On December 22, 2008, the Board of Directors approved a one-time stock option exchange program, subject to stockholder approval (the Option Exchange Program). The Option Exchange Program would permit eligible employees to exchange their outstanding options issued on January 16, 2008 at an exercise price per share of \$33.31 for a lesser number of new options (New Options), with such number of New Options issuable upon exchange calculated pursuant to an exchange ratio. The New Options would have an exercise price not less than 110% of the closing sales price of the Company's common stock on the date of the new grant.

The proposed exchange ratio for a surrendered option will be determined based on the original exercise price of the surrendered option. The Company intends to use an exchange ratio that will result in the issuance of New Options having a fair value approximately equal to the fair value of the surrendered option in the exchange, as determined for financial accounting purposes in accordance with SFAS 123(R). This exchange ratio should not result in any additional compensation expense to the Company in connection with the issuance of the New Options or the cancellation of the surrendered options. As of December 27, 2008, employees holding approximately 820 eligible options in the aggregate would have been eligible to participate in the Option Exchange Program.

(11) Comprehensive Income (Loss)

The Company's items of other comprehensive income (loss) relate foreign currency translation adjustments, and are presented separately on the balance sheet as required.

A reconciliation of comprehensive income (loss) is as follows:

	Three months ended	
	December 27, 2008	December 29, 2007
Net income (loss) as reported	\$ 47,993	\$ (358,608)
Translation adjustment	(1,633)	1,600
Comprehensive income (loss)	\$ 46,360	\$ (357,008)

(12) Business Segments and Geographic Information

The Company reports segment information in accordance with SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information* (SFAS 131). Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company's chief decision-maker, as defined under SFAS 131, is the chief operating officer. The Company reports its business as four segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Diagnostics segment includes the results of Third Wave Technologies, which was acquired in the fourth quarter of fiscal 2008.

Identifiable assets for the four principal operating segments consist of inventories, intangible assets, and property and equipment. The Company has presented all other identifiable assets as corporate assets. Intersegment sales and transfers are not significant. Segment information for the three months ended December 27, 2008 and December 29, 2007 is as follows:

	Three Months Ended	
	December 27, 2008	December 29, 2007
Total revenues		
Breast Health	\$ 199,112	\$ 196,962

Edgar Filing: HOLOGIC INC - Form 10-Q

Diagnostics	134,624	100,312
GYN Surgical	67,949	49,886
Skeletal Health	27,548	24,285
	\$ 429,233	\$ 371,445

Operating income (loss)		
Breast Health	\$ 44,960	\$ 42,672
Diagnostics	24,283	(81,970)
GYN Surgical	19,981	(282,872)
Skeletal Health	4,497	(611)

Table of Contents

	Three Months Ended	
	December 27, 2008	December 29, 2007
	\$ 93,721	\$ (322,781)
Depreciation and amortization		
Breast Health	\$ 10,800	\$ 9,401
Diagnostics	39,346	20,308
GYN Surgical	14,293	5,465
Skeletal Health	1,742	1,389
	\$ 66,181	\$ 36,563
Capital expenditures		
Breast Health	\$ 3,845	\$ 4,877
Diagnostics	1,487	2,843
GYN Surgical	1,942	2,556
Skeletal Health	2,225	1,916
	\$ 9,499	\$ 12,192
	December 27, 2008	September 27, 2008
Identifiable assets		
Breast Health	\$ 1,433,422	\$ 1,435,674
Diagnostics	2,952,622	2,976,854
GYN Surgical	3,064,885	3,080,365
Skeletal Health	31,827	25,151
Corporate	656,609	616,588
	\$ 8,139,365	\$ 8,134,632

There were no customers with balances greater than 10% of accounts receivable as of December 27, 2008 or September 27, 2008, nor any customer that represented greater than 10% of product revenues during the three months ended December 27, 2008 and December 29, 2007.

Export sales from the United States to unaffiliated customers, primarily in Europe, Asia and Latin America, during the three months ended December 27, 2008 and December 29, 2007 totaled approximately \$81,421 and \$67,596, respectively.

Products sold by the Company internationally are manufactured at domestic and international manufacturing locations such as Costa Rica, where much of the GYN Surgical products are currently being manufactured.

Transfers between the Company and its subsidiaries are generally recorded at amounts similar to the prices paid by unaffiliated foreign dealers. All intercompany profit is eliminated in consolidation.

There were no intersegment revenues during the three months ended December 27, 2008.

Export product sales as a percentage of total product sales were as follows:

	Three months ended	
	December 27, 2008	December 29, 2007
Europe	13%	12%

Edgar Filing: HOLOGIC INC - Form 10-Q

Asia	4%	4%
All others	5%	4%
	22%	20%

Table of Contents**(13) Litigation and Other Matters**

On October 5, 2007, Ethicon Endo-Surgery, Inc., a Johnson & Johnson operating company, filed a complaint against the Company and its wholly-owned subsidiary Suros in the United States District Court for the District of Ohio. The complaint alleges that certain of the ATEC biopsy systems manufactured and sold by Suros infringe four Ethicon patents. An amended complaint filed January 11, 2008 additionally asserts claims of unfair competition. The complaint seeks to enjoin Hologic and Suros from conducting acts of unfair competition and infringing the patents as well as the recovery of unspecified damages and costs. A Markman hearing was held on January 8, 2009. Given the early stage of the litigation, the Company is unable to reasonably estimate the ultimate outcome of this case.

On January 9, 2008, Tissue Extraction Devices, LLC filed a complaint against the Company and Suros in the United States District Court for the Northern District of Illinois, alleging infringement of US Patent No. 7,316,726 by certain of the ATEC biopsy systems manufactured and sold by Suros. The complaint seeks to enjoin the Company and Suros from infringing the patents as well as the recovery of damages and costs resulting from the alleged infringement. On May 20, 2008, the judge in Illinois granted the Company's motion to transfer the case to the United States District Court for the Southern District of Indiana. Given the early stage of the litigation, the Company is unable to reasonably estimate the ultimate outcome of this case.

On January 8, 2008, the Company filed a suit against SenoRx in the United States District Court for the District of Northern California for infringement of U.S. Patent Nos. 5,913,813, 6,413,204, and 6,482,142. The complaint seeks to enjoin SenoRx from infringing the patents, recovery of damages and costs and seeks a finding of willful infringement. On February 6, 2008 the Company filed a motion for preliminary injunction seeking to enjoin further sales of the SenoRx Contura device. On April 25, 2008 the judge issued an order denying the motion but ordered the parties to schedule a trial in 60-90 days from the date of the order. A Markman hearing was held on October 14, 2008.

In October 2005, Third Wave, which the Company acquired by way of merger on July 24, 2008, filed a declaratory judgment suit in the United States District Court for the Western District of Wisconsin against Digene Corporation seeking a ruling that its HPV ASRs do not infringe any valid claims of Digene's human papillomavirus related patents. In January 2006, Third Wave reached an agreement with Digene to dismiss the suit without prejudice. Third Wave also agreed that neither party would file a suit against the other relating to the human papillomavirus patents for one year. After this period expired, on January 11, 2007, Digene Corporation filed suit against Third Wave in the United States Court for the Western District of Wisconsin. The complaint alleged patent infringement of unidentified claims of a single patent related to HPV type 52 by Third Wave's HPV ASR product. Third Wave filed its response to Digene's complaint on February 28, 2007, which, in addition to denying the alleged infringement, also asserted that certain Digene sales practices violate certain antitrust laws. After conducting a hearing on June 22, 2007, the court released its claim construction order on July 23, 2007 adopting all of Third Wave's proposed construction. On July 31, 2007, Digene filed a motion to reconsider the court's claim construction. On September 26, 2007, the court issued an order denying Digene's motion for reconsideration in its entirety and upheld the earlier claim construction ruling. In response, in a filing to the court, Digene stated that it believes it will not be able to sustain its claim of infringement. On October 19, 2007 Digene filed a motion for summary judgment on Third Wave's antitrust counterclaims. On November 23, 2007 the court issued an order dismissing Digene's patent infringement claims. On January 11, 2008, the court issued an order granting Digene's motion for summary judgment on Third Wave's antitrust counterclaims. On February 29, 2008 both Third Wave and Digene filed notices of appeal to the Court of Appeals for the Federal Circuit. On June 11, 2008, Digene filed its opening brief asking the Federal Circuit to overturn certain of the district court's claim construction. Oral arguments for the appeal were conducted on February 2, 2009.

The Company is a party to various other legal proceedings arising out of the ordinary course of its business. The Company believes that there are no other proceedings pending against it which, if determined adversely, would have a material adverse effect on its financial condition or results of operations.

(14) Income Taxes

The Company's effective tax rates for the three months ended December 27, 2008 and December 29, 2007 were 34.0% and (1.8)%, respectively. For the three months ended December 27, 2008, the effective tax rate was reduced primarily due to the retroactive reinstatement of the Federal research and development tax credit. The effective tax rate for the three months ended December 29, 2007 was reduced primarily due to the acquired in-process research and development charge related to the Cytoc merger. As of December 27, 2008 the Company has recorded a net deferred tax liability of \$873,000. This liability is net of certain deferred tax assets totaling approximately \$52,000. Management's conclusion that such assets will be recovered is based upon its expectation that future earnings of the Company will provide sufficient taxable income. While the realization of the Company's net recorded deferred tax assets cannot be assured, to the extent that future taxable income against which these tax assets may be applied is not sufficient, some or all of the Company's net recorded deferred tax assets would not be realizable.

The Company had gross unrecognized tax benefits, including interest, of approximately \$21,700 as of December 27, 2008. Of this amount, \$6,800 represents the amount of unrecognized tax benefits as of December 27, 2008 that, if recognized, would result in a reduction of the

Edgar Filing: HOLOGIC INC - Form 10-Q

Company's effective tax rate. At December 29, 2007 the Company had \$20,300 of gross unrecognized tax benefits, \$4,200 of which, if recognized, would result in the reduction of the Company's effective tax rate. However, upon the adoption of SFAS No. 141(R) changes in unrecognized tax benefits following an acquisition generally will affect income tax expense, including

Table of Contents

any changes associated with acquisitions that occurred prior to the effective date of SFAS 141(R). In the next twelve months it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by \$970 due to the expiration of statute of limitations and settlements with taxing authorities, of which \$830 will reduce goodwill and \$140 will reduce the Company's effective tax rate.

The Company's policy is to recognize accrued interest and penalties related to unrecognized tax benefits and income tax liabilities, when applicable, as part of income tax expense in its Consolidated Statements of Operations. As of December 27, 2008, accrued interest was approximately \$840, net of federal benefit. As of December 27, 2008, no penalties have been accrued.

The Company and its subsidiaries are subject to United States federal income tax, as well as income tax of multiple state income and foreign jurisdictions. The current tax returns are open for audit through fiscal 2013.

The Company currently has a tax holiday in Costa Rica that is scheduled to expire in 2015. This tax holiday will not materially reduce the Company's income tax provision for fiscal 2009.

(15) Product Warranties

The Company generally offers a one-year warranty for its products. The Company provides for the estimated cost of product warranties at the time product revenue is recognized with the exception of the Company's R2 CAD and Dimensions digital mammography products for which the Company defers the vendor-specific objective evidence of fair value of the post contract support to be provided during the warranty period. Factors that affect the Company's warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary.

Product warranty activity for the three months ended December 27, 2008 and December 29, 2007 is as follows:

	Balance at beginning of period	Accruals for warranties provided during the period	Accruals for warranties acquired during the period	Write-offs/ payments	Balance at end of period
Three Months Ended:					
December 27, 2008	\$ 9,109	\$ 1,321	\$	\$ (2,306)	\$ 8,124
December 29, 2007	\$ 12,087	\$ 2,829	\$ 591	\$ (2,311)	\$ 13,196

(16) Restructuring Accrual

As a result of the Cytoc merger and the acquisition of Third Wave in the first and fourth quarters of fiscal 2008, respectively, the Company recorded liabilities related to restructuring plans, approved by the previous management of those companies and designed to reduce future operating expenses and recorded liabilities, of approximately \$4,658 and \$7,509, respectively. The Company did not incur any additional restructuring costs related to these plans, and it is anticipated that these costs will be paid in full during fiscal 2009.

Additionally, during fiscal 2008 the Company recorded a liability related to the Cytoc merger in accordance with EITF 95-3, primarily related to the termination of certain employees as well as minimum inventory purchase commitments and other contractual obligations for which business activities have been discontinued.

Changes in the restructuring accrual for the three months ended December 27, 2008 were as follows:

	Three Months Ended December 27, 2008	
	Other	Termination Benefits
Beginning balance, September 27, 2008	\$ 882	\$ 1,309
Adjustments	(207)	(142)
Payments		(249)

Edgar Filing: HOLOGIC INC - Form 10-Q

Ending balance, December 27, 2008

\$ 675

\$

917

As a result of the Cytoc merger, the Company also assumed an arrangement in which the Company is sub-leasing all of its Mountain View facility to a third party for a term of approximately five years, a period of time equivalent to the remainder of the Company's lease of this facility. The sub-lease commenced on July 1, 2007.

Table of Contents**(17) Related Party Transactions**

In May 2006, the Company entered into retention and severance agreements with certain executives that provide for retention payments in cash totaling \$3,000 if these executives remain employed with the Company through December 31, 2008 (the Retention Date). The Company determined that it was probable that these amounts would be paid and, therefore, has been accruing these amounts ratably through the Retention Date. In addition, in connection with the retention and severance agreement, these executives were awarded 108 restricted stock units with an aggregate value of \$2,500 at the time of grant. These restricted stock units cliff vest on the Retention Date. These shares are excluded from the computation of basic earnings per share until the shares vest because the employee is not entitled to the reward of stock ownership. The Company has been recording the \$2,500 of stock-based compensation over the vesting period of the restricted stock units. As a result, the Company recorded stock-based compensation expense of \$234 during each of the three month periods ended December 27, 2008 and December 29, 2007. The \$2,500 has been expensed in full as of December 27, 2008, and the related cash payments and stock issuance were completed in the second quarter of fiscal 2009.

(18) Supplemental Executive Retirement Plan

Effective March 15, 2006, the Company adopted a SERP, to provide non-qualified retirement benefits to a select group of executive officers, senior management and highly compensated employees of the Company. Eligible employees may elect to contribute up to 75% of their annual base salary and 100% of their annual bonus to the SERP. In addition, the Company may elect to make annual discretionary contributions on behalf of participants in the SERP. Each Company contribution is subject to a three year vesting schedule, such that each contribution is one third vested each year and is fully vested three years after the contribution is made. The Company contributions become fully vested upon death or disability of the participant or a change in control of the Company, as defined. Voluntary contributions made by the participant are 100% vested. All voluntary contributions have been recorded as a component of accrued expenses in the accompanying Consolidated Balance Sheets.

Upon enrollment into the SERP, employees make investment elections for both their voluntary contributions and discretionary contributions, if any, made by the Company. Earnings and losses on contributions based on these investment elections are recorded as a component of compensation expense in the period earned.

In both October 2006 and October 2007, the Compensation Committee of the Board of Directors approved a \$1,500 discretionary cash contribution to the SERP for each year respectively. In November 2008, the Compensation Committee of the Board of Directors approved a \$2,825 discretionary contribution to the SERP for fiscal 2008. Discretionary contributions by the Company to the SERP are held in a Rabbi Trust. The Company is recording compensation expense for the SERP discretionary contribution ratably over the three-year vesting period, which totaled \$490 and \$242 in the three months ended December 27, 2008 and December 29, 2007, respectively. The full amount of the discretionary contribution, net of forfeitures, has been recorded as a component of accrued expenses in the accompanying Consolidated Balance Sheets.

The Company has purchased Company-owned group life insurance contracts, in which both voluntary and discretionary Company SERP contributions are invested to fund payment of the Company's and employees' contributed amounts and related earnings, in the amount of \$7,809 which approximates the total of employee voluntary contributions into the plan and the Company's cash portion of its discretionary contribution. The values of these life insurance contracts have been recorded as a component of other long-term assets in the accompanying Consolidated Balance Sheets. Changes in the cash surrender value of life insurance contracts, which resulted in a charge of \$1,100 in the three months ended December 27, 2008 and \$60 in the three months ended December 29, 2007, are recorded as a component of other expense (income), net in the accompanying Consolidated Statements of Operations.

(19) Goodwill and Intangible Assets*Intangible Assets*

The majority of the Company's intangible assets arose in connection with its business combinations. These intangible assets were recorded at fair value and are stated net of accumulated amortization and impairments.

The Company amortizes its intangible assets that have finite lives using either the straight-line method or, if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from 2 to 30 years. If the estimate of an intangible asset's remaining useful life is changed, the Company will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.

Edgar Filing: HOLOGIC INC - Form 10-Q

Subsequent to the Cytoc merger, the Company decided to discontinue the development of Cytoc's Helica product. The Company will not realize any future cash flows from this product. The Company's intangible asset valuation for Cytoc included approximately \$2,900 related to customer relationships for Helica. As a result of the Helica product discontinuation, the Company recorded an impairment charge, as a component of its GYN Surgical segment, of \$2,900 in the first quarter of fiscal 2008.

In accordance with SFAS No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets* (SFAS 144), the Company evaluates the realizability of long-lived assets, which primarily consist of property and equipment and definite lived

Table of Contents

intangible assets (the SFAS 144 Long-Lived Assets), on an annual basis, or more frequently when events or business conditions warrant it, based on expectations of non-discounted future cash flows for each subsidiary. As a result of the Company's conclusion that an interim impairment test of goodwill was required during the first quarter of 2009 (see discussions below), the Company performed in the first quarter of 2009 an interim test for the impairment of long-lived assets as required by SFAS 144.

The interim evaluation of the impairment of long-lived assets, other than goodwill, was based on expectations of non-discounted future cash flows compared to the carrying value of the long-lived asset groups in accordance with SFAS 144. If the sum of the expected non-discounted future cash flows was less than the carrying amount of the SFAS 144 Long-Lived Assets, the Company would recognize an impairment loss. The Company's cash flow estimates were based upon historical cash flows, as well as future projected cash flows derived from the annual Company wide planning process and interim forecasting. The Company believes that its procedures for estimating gross future cash flows are reasonable and consistent with market conditions at the time of estimation. The results of the Company's interim impairment testing under SFAS 144 indicated that there was no impairment of SFAS 144 Long-Lived Assets, other than goodwill, as of December 27, 2008.

Intangible assets consist of the following:

Reporting Segment	Description	Weighted Average Remaining Estimated Amortization Period (in years)	As of December 27, 2008		As of September 27, 2008	
			Gross Carrying Value	Accumulated Amortization	Gross Carrying Value	Accumulated Amortization
Breast Health	Developed Technology	10.36	\$ 293,605	\$ 41,321	\$ 293,689	\$ 35,739
	Customer Relationship	10.17	69,864	16,603	69,319	14,603
	Trade Name	17.85	24,646	2,706	24,663	2,309
	Order Backlog	0.00	800	800	800	800
	Patents	10.02	4,164	665	4,085	668
Diagnostics	Developed Technology	13.77	1,074,100	78,450	1,074,700	55,862
	Customer Relationship	13.75	224,900	13,700	224,900	7,837
	Trade Name	24.91	71,500	6,380	71,500	5,009
	Capitalized License Fees	5.45	4,363	280	4,364	112
GYN Surgical	Developed Technology	13.75	767,300	30,523	767,300	20,967
	Customer Relationship	13.75	189,917	2,295	189,917	69
	Trade Name	24.83	50,800	3,398	50,800	2,632
Skeletal Health	Patents	7.89	7,098	6,879	7,098	6,877
	Customer Relationship	7.78	145	4		
Totals			\$ 2,783,202	\$ 204,004	\$ 2,783,135	\$ 153,484

Amortization expense related to developed technology, capitalized license fees and patents is classified as a component of cost of product sales amortization of intangible assets in the accompanying Consolidated Statements of Operations. Amortization expense related to customer relationship and trade name is classified as a component of amortization of acquired intangible assets in the accompanying Consolidated Statements of Operations.

The estimated remaining amortization expense for each of the five succeeding fiscal years:

Remaining nine months ended September 26, 2009	\$ 151,008
Fiscal 2010	223,748
Fiscal 2011	230,213
Fiscal 2012	235,627
Fiscal 2013	228,513

Goodwill

Edgar Filing: HOLOGIC INC - Form 10-Q

In accordance with SFAS No. 142, *Goodwill and Other Intangible Assets* (SFAS 142), the Company tests goodwill at the reporting unit level for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, a significant adverse change in legal factors or business climate and an adverse action or assessment by a regulator.

In prior years, the Company conducted its annual impairment test of goodwill for certain of its reporting units (its historical reporting units prior to the Cytoc merger) as of the last day of the second quarter. In performing the test, the Company utilized the two-step approach prescribed under SFAS 142. The first step requires a comparison of the carrying value of the reporting units, as defined, to the fair value of these units. The Company considered a number of factors to determine the fair value of a reporting unit,

Table of Contents

including an independent valuation, to conduct this test. The valuation is based upon expected future discounted operating cash flows of the reporting unit as well as analysis of recent sales or offerings of similar companies. The Company bases the discount rate used to arrive at a present value as of the date of the impairment test on the Company's weighted average cost of capital. If the carrying value of a reporting unit exceeds its fair value, the Company will perform the second step of the goodwill impairment test to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of a reporting unit's goodwill to its carrying value.

In the fourth quarter of fiscal 2008, the Company changed the measurement date from the last day of its second quarter to the first day of its fourth quarter, in order to provide additional time to quantify the fair value of its reporting units and to evaluate the results of the impairment testing. This change did not delay, accelerate or avoid an impairment charge. This change did not have an effect on the Company's financial performance or results of operations, nor was there any impact on prior periods' financial statements under the requirements of SFAS No. 154, *Accounting Changes and Error Corrections* (SFAS 154). The retrospective application as required under SFAS 154 was not necessary as no impairment charges had been recorded in any previously recorded financial statements nor did the change in measurement date cause any impairments.

As a result of the change in the measurement date for the Company's annual goodwill impairment test for its historical reporting units from the last day of the second quarter of the fiscal year to the first day of the fourth quarter of the fiscal year, the Company has evaluated, in accordance with paragraph 27 of SFAS 142, whether the detailed determination of fair value of its historical reporting units as of March 29, 2008 could be carried forward to the first day of its fiscal fourth quarter of 2008 or if a new test of goodwill impairment was required to be performed for these historical reporting units. In its evaluation, the Company noted that the assets and liabilities of the reporting units had not changed significantly, there was sufficient margin between the carrying amount and fair value determination for each reporting unit and no events or circumstances related to these reporting units would suggest that a current fair value determination of reporting units would result in a valuation lower than the carrying amount of the reporting units. Based on this evaluation, the Company believed it sufficiently met the requirements of paragraph 27 of SFAS 142 to carry forward its estimate of fair value for these reporting units.

The Company conducted its annual impairment test of goodwill for its new reporting units as a result of the Company's acquisition of Cytac Corporation as of the first day of the fourth quarter of fiscal 2008. In performing the test, the Company utilized the two-step approach prescribed under SFAS 142. The Company considered a number of factors to determine the fair value of a reporting unit, including an independent valuation to conduct this test. The valuation was based upon expected future discounted operating cash flows of the reporting unit as well as analysis of recent sales or offerings of similar companies. The Company based the discount rate used to arrive at a present value as the date of the impairment test on the Company's weighted average cost of capital. The fair value of each reporting unit was determined to be in excess of each reporting unit's carrying value and as a result the second step of the impairment test was not required.

Based upon a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of the Company's market capitalization significantly below the book value of the Company's net assets, the Company concluded that potential goodwill impairment indicators existed as of December 27, 2008. As a result, the Company is performing an interim goodwill impairment analysis as of December 27, 2008 in accordance with SFAS 142. The Company has engaged an outside valuation advisor to assist in valuing the Company's reporting units and preparing the goodwill impairment analysis. Step 1 of the Company's impairment analysis under SFAS 142 indicates that the carrying value of the net assets of certain reporting units, primarily acquired in connection with the Cytac acquisition, exceeds the estimated fair value of those reporting units. These reporting units had goodwill totaling approximately \$4,000,000, as of December 27, 2008. As a result, the Company will be required to perform Step 2 of the goodwill impairment test under SFAS 142 to determine the amount, if any, of goodwill impairment charges by reporting unit to be recorded by the Company. The Company expects to complete the Step 2 analysis by the end of its fiscal second quarter, March 28, 2009. The Step 2 analysis under SFAS 142 requires the Company to perform a theoretical purchase price allocation for each of these reporting units to determine the implied fair value of goodwill and to compare the implied fair value of goodwill to the recorded amount of goodwill by reporting unit. In the event that the Company determines that its goodwill is impaired in whole or in part, the Company will record a non-cash charge, which could be material, in the second quarter of fiscal 2009. As the goodwill impairment analysis under SFAS 142 is not complete, the Company cannot determine if an impairment charge is probable and cannot reasonably estimate the amount of any potential impairment charge.

The estimate of fair value requires significant judgment. Any loss resulting from the SFAS 142 impairment analysis would be reflected in operating income (loss) in the Company's Consolidated Statements of Operations. The impairment testing process is subjective and requires judgment at many points throughout the analysis. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges for these assets not previously recorded. Any potential impairment charges related to goodwill would have no impact on the Company's cash balances or compliance with financial covenants under its Amended and Restated Credit Agreement.

Table of Contents

The allocation of goodwill by reporting segment consists of the following:

	Balance as of December 27, 2008	Balance as of December 29, 2007
Breast Health	\$ 928,536	\$ 930,672
Diagnostics	1,494,594	1,486,988
GYN Surgical	2,023,804	2,024,639
Skeletal Health	8,174	8,197
	\$ 4,455,108	\$ 4,450,496

The \$4,600 increase to goodwill during the three months ended December 27, 2008 primarily includes an \$11,400 decrease to the estimated tax net operating loss carryforward acquired as a result of the Third Wave acquisition as a result of an increase in the valuation allowance related to these assets acquired where the Company determined that it was more likely than not that these assets would be realized, offset by decreases in goodwill for increases to the tax net operating loss carryforwards acquired as a result of the Cytoc and R2 acquisitions in the amounts of \$2,100 and \$2,000, respectively, and an increase in the preliminary estimate of other tax attributes acquired in the Third Wave acquisition of \$3,200.

(20) Recent Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141 (Revised 2007), *Business Combinations* (SFAS 141(R)). This Statement retains the fundamental requirements in SFAS 141 that the acquisition method of accounting (which SFAS 141 called the purchase method) be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) requires an acquirer to recognize the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the Statement. That replaces SFAS 141's cost-allocation process, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values. The Statement retains the guidance in SFAS 141 for identifying and recognizing intangible assets separately from goodwill. SFAS 141(R) will now require acquisition costs to be expensed as incurred, restructuring costs associated with a business combination to be expensed prior to the acquisition date and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally to affect income tax expense. SFAS 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, which is the Company's 2010 fiscal year. Early adoption is prohibited. The Company is currently evaluating the impact that the adoption of SFAS 141(R) will have on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements - An amendment of ARB No. 51* (SFAS 160). SFAS 160 amends Accounting Research Bulletin (ARB) No. 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. SFAS 160 clarifies that changes in a parent's ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this Statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, which is the Company's 2010 fiscal year. Early adoption is prohibited.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS 161), which amends SFAS 133 by requiring expanded disclosures about an entity's derivative instruments and hedging activities. SFAS 161 requires increased qualitative, quantitative, and credit-risk disclosures, including (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. The Company is required to adopt SFAS 161 effective for the quarter ended March 28, 2009. Since SFAS 161 requires only additional disclosures concerning derivatives and hedging activities, its adoption will not affect the Company's financial condition, results of operations or cash flows.

Table of Contents

In April 2008, the FASB issued FASB Staff Position (FSP) No. 142-3, *Determination of the Useful Life of Intangible Assets*, which amends the factors that must be considered in developing renewal or extension assumptions used to determine the useful life over which to amortize the cost of a recognized intangible asset under SFAS 142. The objective of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R). The FSP is effective for financial statements for fiscal years beginning after December 15, 2008, which will be the beginning of fiscal 2010 for the Company. The Company is currently evaluating the impact that the adoption of this FSP will have on its consolidated financial statements.

In May 2008, the FASB issued FSP No. APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)*. This FSP applies to convertible debt instruments that, by their stated terms, may be settled in cash (or other assets) upon conversion, including partial cash settlement, unless the embedded conversion option is required to be separately accounted for as a derivative under SFAS 133. The liability and equity components of convertible debt instruments within the scope of this FSP must be separately accounted for in a manner that will reflect the entity's nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. The excess of the principal amount of the debt over the amount ultimately allocated to the liability component is required to be amortized to interest expense using the interest method. This FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. As a result, the Company will adopt this standard at the beginning of fiscal 2010. This FSP must be applied retrospectively to all periods presented. The retrospective adoption of this FSP will increase the Company's historical reported interest expense from December 10, 2007 (issuance date of the Convertible Notes - See Note 6) forward.

The adoption of FSP APB 14-1 will have no impact on the Company's actual past or future cash flows. However, upon adoption in fiscal 2010 the Company will restate prior periods by reclassifying approximately \$470,000 of its Convertible Notes to additional paid-in capital, resulting in a debt discount. It is estimated that the Company's non-cash interest expense will increase by approximately \$2,600 for the three months ended December 29, 2007 and \$15,900 for the three months ended December 27, 2008, resulting in a restated diluted net loss per share of approximately \$1.66 for the three months ended December 29, 2007 and restated diluted net income per share of approximately \$0.15 for the three months ended December 27, 2008.

On May 5, 2008, SFAS No. 162, the *Hierarchy of Generally Accepted Accounting Principles* (SFAS 162) was issued. This standard identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements that are presented in conformity with generally accepted accounting principles in the U.S. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

In June 2008, the FASB ratified the consensus reached on EITF Issue No. 07-05, *Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock* (EITF 07-05). EITF 07-05 clarifies the determination of whether an instrument (or an embedded feature) is indexed to an entity's own stock, which would qualify as a scope exception under SFAS 133. EITF 07-05 is effective for financial statements issued for fiscal years beginning after December 15, 2008. Early adoption for an existing instrument is not permitted. The Company has concluded that upon the adoption of this standard, the embedded derivative option in the Company's Convertible Notes (See Note 6) will continue to be considered indexed to the Company's own stock. As a result, the adoption of EITF 07-05 is not expected to have a material impact on the Company's financial condition or results of operations.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY STATEMENT

This report contains forward-looking information that involves risks and uncertainties, including statements regarding our plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding various estimates we have made in preparing our financial statements, statements regarding expected future trends relating to our results of operations and the sufficiency of our capital resources. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect our business and prospects include without limitation:

the risk that the current crisis affecting world financial markets may adversely affect our business and prospects;

the importance of third party reimbursement policies to support the sales and market acceptance of our products;

the risk that we may fail to successfully realize the anticipated benefits from combining recently acquired businesses, technologies, product lines, and products, including Third Wave and Cytoc, with our business for a number of reasons, including the following:

we may be unable to successfully integrate the acquired businesses, which may result in us not operating as effectively and efficiently as expected;

we may be unable to achieve the expected synergies from an acquisition or it may take longer than expected to achieve those synergies;

an acquisition may result in future impairment charges related to diminished fair value of businesses acquired as compared to the price we paid for them;

an acquisition may involve restructuring operations or reductions in workforce which may result in substantial charges to our operations;

an acquisition may involve unexpected costs or liabilities, or the effects of purchase accounting may be different from our expectations; and

the acquired businesses may be adversely affected by future legislative, regulatory, or tax decisions and/or changes as well as other economic, business and/or competitive factors.

risks associated with the continued market acceptance of our products, as well as the limited number of customers for our ThinPrep system;

manufacturing risks that may limit our ability to increase commercial production of our Selenia systems and other of our digital products, including our reliance on a single or a limited number of suppliers for some key components of our products as well as the

Edgar Filing: HOLOGIC INC - Form 10-Q

need to comply with especially high standards for those components and in the manufacture of direct radiography products in general;

uncertainties inherent in the development of new products and the enhancement of existing products, including technical, FDA approval/clearance and other regulatory risks, cost overruns and delays;

the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated;

our ability to predict accurately the demand for our products, and products under development;

our ability to successfully manage our international operations, including fluctuations in exchange rates;

our ability to develop strategies to address our markets successfully and the risk that the markets for our products may not develop or continue as expected;

the early stage of market development for certain of our products;

expenses and uncertainties relating to litigation, product liability claims and allegations of infringement of third party intellectual property rights;

technical innovations that could render products marketed or under development by us obsolete and our ability to protect our proprietary technologies;

competition;

an adverse change in the projected discounted cash flows from our acquired businesses or the business climate in which they operate, including the continuation of the current financial and economic turmoil, could require us to incur an impairment charge which would have an adverse impact on our operating results.

Table of Contents

Based upon a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of our market capitalization significantly below the book value of our net assets, we concluded that potential goodwill impairment indicators existed as of December 27, 2008. As a result, we are performing an interim goodwill impairment analysis as of December 27, 2008 in accordance with SFAS No. 142, *Goodwill and Other Intangible Assets* (SFAS 142). We have engaged an outside valuation advisor to assist in valuing our reporting units and preparing the goodwill impairment analysis. Step 1 of the impairment analysis under SFAS 142 indicates that the carrying value of the net assets of certain reporting units, primarily acquired in connection with the Cytyc acquisition, exceeds the estimated fair value of those reporting units. These reporting units had goodwill totaling approximately \$4.0 billion as of December 27, 2008. As a result, we will be required to perform Step 2 of the goodwill impairment test under SFAS 142 to determine the amount, if any, of goodwill impairment charges by reporting unit to be recorded. We expect to complete the Step 2 analysis by the end of our fiscal second quarter, March 28, 2009. The Step 2 analysis under SFAS 142 requires us to perform a theoretical purchase price allocation for each of these reporting units to determine the implied fair value of goodwill and to compare the implied fair value of goodwill to the recorded amount of goodwill by reporting unit. In the event that we determine that our goodwill is impaired in whole or in part, we will record a non-cash charge, which could be material, in the second quarter of fiscal 2009. As the goodwill impairment analysis under SFAS 142 is not complete, we cannot determine if an impairment charge is probable and cannot reasonably estimate the amount of any potential impairment charge.

Other factors that could adversely affect our business and prospects are described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended September 27, 2008 and in Part II, Item 1A of this report. The risks included above and in such reports are not exhaustive. Except as required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such forward-looking statement is based.

OVERVIEW

We are a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. Historically, we have developed, manufactured and marketed products focused on mammography, breast care and osteoporosis assessment. In October 2007, we completed our business combination with Cytyc Corporation (Cytyc), a company that develops, manufactures and markets complementary products covering a range of cancers and women's health applications, including cervical cancer screening, prenatal diagnostics and partial breast radiation therapy. On July 24, 2008, we completed our acquisition of Third Wave Technologies, Inc. (Third Wave), a company that develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader chemistry.

We have historically focused our resources on developing systems and subsystems offering superior image quality and diagnostic accuracy, which has enabled us to capture significant market share and customer loyalty, despite the presence of large competitors. Our combination with Cytyc enabled us to benefit from Cytyc's strengths in the fields of obstetrics, gynecology, radiation oncology and minimally invasive surgery. Our acquisition of Third Wave enabled us to further expand our offerings into the clinical molecular diagnostics market utilizing Third Wave's Invader chemistry and its human papillomavirus (HPV) test currently awaiting FDA approval.

Our breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), breast biopsy guidance systems, minimally invasive breast biopsy and tissue extraction devices and breast brachytherapy products. Our new Dimensions digital mammography product received CE mark approval in Europe in fiscal 2008.

Our diagnostics products include the ThinPrep System, which is primarily used in cytology applications such as cervical cancer screening, and the Full Term Fetal Fibronectin Test, which offers clinical and cost benefits for the assessment of the risk of pre-term birth. Through our recent acquisition of Third Wave, we have added in vitro diagnostic tests using Third Wave's Invader technology, allowing researchers and clinical laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing and testing for other mutations associated with genetic predispositions and other diseases such as Cystic Fibrosis. We have also submitted applications to the FDA for pre-market approval (PMA) of two HPV tests.

Our GYN surgical products include the NovaSure Impedance Controlled RF Ablation System (NovaSure System), which enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner in order to eliminate or reduce their bleeding, and the Adiana Complete Transcervical Sterilization (TCS) System, which is a form of permanent female contraception intended as an alternative to tubal ligation for which we are seeking a PMA from the FDA. The Adiana TCS system received CE mark approval in Europe in the second quarter of fiscal 2009.

Our skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, our Fluorscan mini C-arm imaging products and our Esaote line of extremity Magnetic Resonance Imaging (MRI) systems which are manufactured

by an original equipment manufacturer.

Table of Contents

We were incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. Unless the context otherwise requires, references to us, we, Hologic or our company refer to Hologic, Inc. and each of its consolidated subsidiaries.

On April 2, 2008, we effected a two-for-one stock split in the form of a stock dividend. The stock split has been retroactively reflected in the Management Discussion and Analysis of Financial Condition and Results of Operation section of this report.

RECENT ECONOMIC DEVELOPMENTS

Market acceptance of our medical products in the United States and other countries is dependent upon the medical equipment purchasing and procurement practices of our customers, patient demand for our products and procedures and the reimbursement of patient's medical expenses by government healthcare programs, private insurers or other healthcare payors. The current uncertainty surrounding world financial markets may result in the purchasers of medical equipment decreasing their medical equipment purchasing and procurement activities. Additionally, constrictions in world credit markets may result in our customers having increased difficulty securing the financing necessary to purchase our products which may result in decreased sales. Widespread economic uncertainty may also result in cost-conscious consumers making fewer elective trips to their physicians and specialists which could result in reduced demand for our products and procedures. Furthermore, governments around the world facing tightening budgets could move to further reduce the reimbursement rates offered by government sponsored healthcare programs. If the current economic condition results in the occurrence of any of these events, our business and prospects may be adversely affected.

Recently the value of the U.S. dollar has strengthened against the value of many foreign currencies. A majority of our sales to international dealers are denominated in U.S. dollars. The strengthening of the U.S. dollar makes these products less competitive in international markets and may impact sales and margins over time. In addition, we have international sales, principally in our Diagnostics segment, that are denominated in foreign currencies. The value of these sales will decrease as the U.S. dollar strengthens. We believe that the strengthening of the U.S. dollar, if it persists, may have a material adverse effect on our international sales and margins.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based upon our interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition for multiple element arrangements, allowance for doubtful accounts, reserves for excess and obsolete inventories, valuations and purchase price allocations related to business combinations, expected future cash flows used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, pension liabilities, contingent liabilities, tax reserves and recoverability of our net deferred tax assets and related valuation allowance. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates if past experience or other assumptions do not turn out to be substantially accurate. Any differences may have a material impact on our financial condition and results of operations. For a discussion of how these and other factors may affect our business, see the Cautionary Statement above and Management's Discussion and Analysis of Financial Condition and Results of Operations Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 27, 2008 and in Part II, Item 1A of this report.

Based upon a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of our market capitalization significantly below the book value of our net assets, we concluded that potential goodwill impairment indicators existed as of December 27, 2008. As a result, we are performing an interim goodwill impairment analysis as of December 27, 2008 in accordance with SFAS No. 142, *Goodwill and Other Intangible Assets* (SFAS 142). We have engaged an outside valuation advisor to assist in valuing our reporting units and preparing the goodwill impairment analysis. Step 1 of the impairment analysis under SFAS 142 indicates that the carrying value of the net assets of certain reporting units, primarily acquired in connection with the Cytac acquisition, exceeds the estimated fair value of those reporting units. These reporting units had goodwill totaling approximately \$4.0 billion as of December 27, 2008. As a result, we will be required to perform Step 2 of the goodwill impairment test under SFAS 142 to determine the amount, if any, of goodwill impairment charges by reporting unit to be recorded. We expect to complete the Step 2 analysis by the end of our fiscal second quarter, March 28, 2009. The Step 2 analysis under SFAS 142 requires us to perform a theoretical purchase price allocation for each of these reporting units to determine the implied fair value of goodwill and to compare the implied fair value of goodwill to the recorded amount of goodwill by reporting unit. In the event that we determine that our goodwill is impaired in whole or in part, we will record a non-cash charge, which could be material, in the second quarter of 2009. As the goodwill impairment analysis under SFAS 142 is not complete, we cannot determine if an impairment charge is probable and cannot reasonably estimate the amount of any potential impairment charge.

Edgar Filing: HOLOGIC INC - Form 10-Q

The estimate of fair value requires significant judgment. Any loss resulting from the impairment test would be reflected in operating income (loss) in our Consolidated Statements of Operations. The impairment testing process is subjective and requires judgment at many points throughout the analysis. If these estimates or their related assumptions change in the future, we may be required to record impairment charges for these assets not previously recorded.

Table of Contents

The critical accounting estimates used in the preparation of our financial statements that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this report are described in Management's Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 27, 2008, and as set forth below. There have been no material changes to our critical accounting policies from those set forth in our Annual Report.

Valuation of Acquired In-Process Research and Development - Third Wave Acquisition

As part of the preliminary purchase price allocation for our acquisition of Third Wave, approximately \$195.2 million of the purchase price has been allocated to acquired in-process research and development projects. The amounts allocated to acquired in-process research and development represents programs for which some research and development has been completed, but technological feasibility has not been determined or FDA approval is pending. The amount allocated to acquired in-process research and development related to the Third Wave acquisition represents the estimated fair value based on risk-adjusted cash flows related to these projects using a discount rate of 20%. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products. The fair value attributable to these in-process projects was expensed at the time of the acquisition. If the projects are not successful or completed in a timely manner, we may not realize the financial benefits expected for these projects or for the transaction as a whole.

The most significant acquired in-process technology related to the HPV Cervista High Risk (HR) screening, for which we estimated a value of approximately \$151.2 million. We currently sell HPV reagents that detect certain high risk HPV types as Analyte Specific Reagents (ASRs). In 2006, Third Wave began clinical trials for PMA submissions to the FDA for Cervista HR. We submitted the PMA in April 2008 and we are anticipating FDA approval in the first half of calendar 2009. Subsequent to receiving FDA approval, we expect to discontinue selling the HPV ASRs and only sell HPV In Vitro Diagnostics (IVDs). As such, the HPV in-process research and development relates only to the HPV IVDs and the HPV ASRs were valued as Completed Technology. The estimated cost to complete this technology was approximately \$19.3 million.

The estimated cost to complete Third Wave's remaining in-process research and development projects in the aggregate was \$9.8 million.

Valuation of Acquired In-Process Research and Development - Cytoc Merger

As part of the purchase price allocation for our business combination with Cytoc, we allocated approximately \$370.0 million of the purchase price to acquired in-process research and development projects. The amount allocated to acquired in-process research and development represents the estimated fair value based on risk-adjusted cash flows related to in-process projects that have not yet reached technological feasibility and have no alternative future uses as of the date of the merger. The primary basis for determining the technological feasibility of these projects is obtaining regulatory approval to market the underlying products. The fair value attributable to these in-process projects is expensed at the time of the business combination. If the projects are not successful or completed in a timely manner, we may not realize the financial benefits expected for these projects or for the transaction as a whole.

The fair value assigned to acquired in-process research and development was determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting net cash flows from the projects, and discounting the net cash flows to their present value. The revenue projections used to value the acquired in-process research and development was based on estimates of relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The resulting net cash flows from such projects were based on our estimates of cost of sales, operating expenses, and income taxes from such projects.

The rates utilized to discount the net cash flows to their present value were based on estimated cost of capital calculations and the implied rate of return from the transaction model plus a risk premium. Due to the nature of the forecasts and the risks associated with the developmental projects, appropriate risk-adjusted discount rates were used for the in-process research and development projects. The discount rates are based on the stage of completion and uncertainties surrounding the successful development of the purchased in-process technology projects.

The acquired in-process research and development of Cytoc related to the following research and development projects: Adiana Complete TransCervical Sterilization (TCS) system and expanded labeling of the NovaSure System, Gestiva, the ThinPrep Imaging System, the ThinPrep Processor and Helica.

The most significant acquired in-process technology relates to the Adiana TCS System for which we estimated a value of approximately \$220.0 million. The system, currently under review by the FDA, is an incisionless trans-cervical permanent sterilization device intended to be performed as an office-based procedure. It consists of three different parts: a disposable applicator, an implantable polymer matrix and a radio frequency controller. In January 2008, the FDA requested an additional year of clinical trial data for the product, which we have since

Edgar Filing: HOLOGIC INC - Form 10-Q

completed. We currently anticipate additional costs of approximately \$0.4 million and a delay in the commercial release of this product until at least the third quarter of fiscal 2009. However, we do not believe this delay will have a material adverse impact on our results of operations.

Table of Contents

Subsequent to the Cytyc merger, we decided to discontinue the development of Cytyc's Helica Thermal Coagulator System product. We will not incur any further costs or realize any future cash flows from this product. Our intangible asset valuation for Cytyc included approximately \$2.9 million related to customer relationships for Helica. As a result of the Helica product discontinuation, we recorded an impairment charge of \$2.9 million during the first quarter of fiscal 2008.

The other in-process research and development projects we acquired in our business combination with Cytyc were at different stages of development, ranging from the early stages of development to Phase IIB prototype building, ongoing clinical trials and submission to the FDA of PMA and drug applications. FDA approval or clearance has not been granted for any of the products classified as in-process research and development, nor had Cytyc received any foreign approvals or clearances for any of these products. All products classified as in-process research and development require various levels of in-house and external testing, clinical trials and approvals from the FDA before these future products can be marketed. The estimated cash requirements in the aggregate to complete these remaining products was expected to be approximately \$5.7 million.

The successful development of new products and product enhancements is subject to numerous risks and uncertainties, both known and unknown, including, unanticipated delays, access to capital, budget overruns, technical problems and other difficulties that could result in the abandonment or substantial change in the design, development and commercialization of these new products and enhancements including, for example, changes requested by the FDA in connection with PMA or New Drug Applications (NDAs) for products or 510(k) notification. Given the uncertainties inherent with product development and introduction, we cannot provide assurance that any of our product development efforts will be successful on a timely basis or within budget, if at all. Our failure to develop new products and product enhancements on a timely basis or within budget could harm our results of operations and financial condition.

RESULTS OF OPERATIONS

Our results of operations include the results of Cytyc's operations for the ten week period in the first quarter of fiscal 2008, following the completion of our business combination with Cytyc on October 22, 2007, and for the full thirteen week period in the first quarter of fiscal 2009.

As a result of the Cytyc merger, we reassessed our segment reporting based on the operating and reporting structure of the combined company. Beginning in fiscal 2008, we combined our previously reported Other business segment with our Breast Health (formerly Mammography/Breast Care) and Skeletal Health (formerly Osteoporosis) segments, to better reflect how we view our operations and manage our business. Our Other business segment previously included AEG, mini C-arm, extremity MRI, conventional general radiography service and digital general radiography systems businesses. The AEG business is now part of Breast Health while the remaining reporting units are part of Skeletal Health.

In addition, we are reporting two new operating segments: Diagnostics and GYN Surgical. Diagnostics includes the ThinPrep Products and the FullTerm Fetal Fibronectin test, acquired as part of Cytyc's purchase of Adeza in March 2007, and GYN Surgical includes the NovaSure system and the Adiana TCS system under development. The MammoSite Radiation Therapy system, previously part of Cytyc's surgical reporting segment, which is a single-use device for the treatment of early-stage breast cancer, is now part of our Breast Health segment. Third Wave, which was acquired in July of 2008, is being reported as part of our Diagnostics segment.

We now report our business as four segments; Breast Health, Diagnostics, GYN Surgical and Skeletal Health. Prior periods have been restated to conform to this presentation.

All dollar amounts in tables are presented in thousands.

Product Sales.

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Revenue	Amount	% of Total Revenue	Amount	%
<i>Product Sales</i>						
Breast Health	\$ 158,901	37%	\$ 170,500	46%	\$ (11,599)	(7)%
Diagnostics	133,512	31%	98,161	26%	35,351	36%
GYN Surgical	67,513	16%	49,469	13%	18,044	36%
Skeletal Health	20,182	5%	16,660	5%	3,522	21%

Edgar Filing: HOLOGIC INC - Form 10-Q

\$ 380,108	89%	\$ 334,790	90%	\$ 45,318	14%
------------	-----	------------	-----	-----------	-----

33

Table of Contents

In the current three month period, our product sales increased 14% compared to the corresponding period in the prior year, primarily due to the additional revenues from Cytyc's Diagnostics segment of approximately \$35.4 million, including \$8.5 million from Third Wave, and Cytyc's GYN Surgical segment of approximately \$18.0 million due to the inclusion of these segments for a full quarter (13 weeks) for the first quarter of fiscal 2009 versus the inclusion of only 10 weeks (date of acquisition through quarter-end) of operating results for the first quarter of fiscal 2008, partially offset by a decrease in revenues from our Breast Health products of approximately \$11.6 million.

Breast Health product sales decreased 7% in the current quarter compared to the corresponding period in the prior year, primarily due to a \$13.2 million decrease in digital mammography systems sales primarily as a result of a reduction in the number of Selenia full field mammography systems and related components, including R2 CAD software, sold domestically. We attribute the decrease in digital mammography system sales primarily to cost pressures faced by hospitals due to the worldwide economic instability which has resulted in longer sales processes and delays in capital equipment purchases domestically. This decrease was partially offset by a \$5.3 million increase in revenues from our Suros breast biopsy products. The increase in Suros breast biopsy product sales was primarily attributable to an increase in the number of ATEC and Celero biopsy devices sold domestically.

Diagnostics product sales, which include ThinPrep, FullTerm and Third Wave, were \$133.5 million in the current quarter compared to \$98.2 million for the corresponding period in the prior year, due to the inclusion of Cytyc results for the full quarter in the current year as compared to 10 of the 13 weeks in the prior year, as well as the addition of Third Wave revenues in the current year of approximately \$8.5 million. We acquired Third Wave in July 2008.

GYN Surgical product sales, which include our NovaSure products and Adiana TCS system under development, were \$67.5 million in the current quarter compared to \$49.5 million for the corresponding period in the prior year, due to the inclusion of Cytyc results for the full quarter in the current year as compared to 10 of the 13 weeks in the prior year, as well as a significant increase in the number of NovaSure systems sold in the current quarter.

Skeletal Health product sales increased 21% in the current quarter compared to the corresponding period in the prior year, primarily due to a \$3.0 million increase in osteoporosis assessment product sales and a \$1.1 million increase in mini C-arm sales worldwide, partially offset by a \$0.7 million decrease in extremity MRI sales. The increase in osteoporosis assessment product sales was due to an increase in the number of bone densitometry systems sold worldwide, partially offset by a slight decrease in the average selling prices internationally. The increase in mini C-arm sales was primarily due to an increase in the number of units sold domestically and, to a lesser extent, internationally. The decrease in extremity MRI sales was due to a decrease in the number of systems sold.

In the first three months of fiscal 2009, approximately 78% of product sales were generated in the United States, 13% in Europe, 4% in Asia, and 5% in other international markets. In the first three months of fiscal 2008, approximately 80% of product sales were generated in the United States, 12% in Europe, 4% in Asia, and 4% in other international markets. The decrease in the percentage of product sales generated in the United States in fiscal 2009 is primarily due to the reduction in digital mammography system sales domestically.

Service and Other Revenues.

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Revenue	Amount	% of Total Revenue	Amount	%
<i>Service and Other Revenues</i>	\$ 49,125	11%	\$ 36,655	10%	\$ 12,470	34%

Service and other revenues is primarily comprised of revenue generated from our field service organization to provide ongoing service, installation and repair of our products. Service and other revenues increased 34% in the current quarter compared to the corresponding period of the prior year. This increase was primarily due to an increase in service and other revenues of \$13.7 million in our Breast Health segment, primarily due to an increase in service contract revenues related to our full field digital mammography systems sold in the current and prior periods. We believe that the increase in our Breast Health service and other revenues reflects the continued growth in our installed base of systems and detectors.

Table of Contents**Cost of Product Sales.**

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007		Amount	%
	Amount	% of Product Sales	Amount	% of Product Sales		
<i>Cost of Product Sales</i>	\$ 123,715	33%	\$ 149,077	45%	\$ (25,362)	(17)%

The cost of product sales decreased 17% in the current quarter compared to the corresponding period in the prior year primarily due to \$41.5 million of costs included in the first quarter of fiscal 2008 related to sales of acquired Cytyc inventory that was written up to fair value for purchase accounting purposes, decreased product sales of our Selenia systems in the first quarter of fiscal 2009 as discussed above and, to a lesser extent, a \$2.0 million MRI inventory charge recorded in the first quarter of 2008. These decreases in cost of product sales were partially offset by increased expenses associated with the inclusion of Cytyc product costs for the full quarter in the current year as compared to 10 of the 13 weeks in the prior year quarter, increased NovaSure product sales and Third Wave-related activity. Included in the Third Wave cost of product sales in the first quarter of fiscal 2009 is approximately \$0.6 million of additional costs related to sales of acquired Third Wave inventory that was written up to fair value for purchase accounting purposes as of the date of acquisition. During the fourth quarter of fiscal 2008, we determined that certain amounts previously classified as a component of *Cost of Service and Other Revenues* should be reclassified to *Cost of Product Sales*. We determined that the reclassification was not material to our consolidated financial statements and corrected the classification in the fourth quarter of fiscal 2008. These amounts totaled \$9.3 million for the three months ended December 29, 2007, and have been reclassified to *Cost of Product Sales* to conform with the current period. Additionally, royalty expense previously recorded within *cost of service and other revenues* totaling \$0.4 million for the three months ended December 29, 2007 has been reclassified to *cost of product sales* to conform with the current period presentation.

The cost of product sales as a percentage of product revenue in the first quarter of fiscal 2009 was 33% as compared to 45% in the prior year. These costs as a percentage of product sales decreased primarily due to the \$43.5 million of charges that were included in product cost of sales in the first quarter of 2008 discussed above. These costs as a percentage of product sales also decreased due to the increase in sales of the Diagnostics and GYN Surgical products which earn higher gross margins compared to the mammography products, which declined in the current period.

Cost of Product Sales Amortization of Intangible Assets.

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007		Amount	%
	Amount	% of Product Revenue	Amount	% of Product Revenue		
<i>Cost of Product Sales Amortization of Intangible Assets</i>	\$ 37,746	10%	\$ 20,155	6%	\$ 17,591	87%

Cost of product sales amortization of intangible assets substantially relates to acquired developed technology and know-how that are a result of our acquisitions. These intangible assets are generally being amortized over their estimated useful lives of between 8.5 and 15 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows. The \$17.6 million increase in these costs primarily relates to \$15.5 million in additional Cytyc-related amortization based on the pattern of amortization and amortization related to the Third Wave acquisition.

Table of Contents**Cost of Service and Other Revenues.**

	Three Months Ended		Three Months Ended		Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Service Revenue	Amount	% of Service Revenue	Amount	%
<i>Cost of Service and Other Revenues</i>	\$ 37,107	76%	\$ 34,378	94%	\$ 2,729	8%

Cost of service and other revenues increased in absolute dollars primarily due to personnel and other costs to expand our service capabilities for breast health, especially in the United States, to support our installed base of our breast health products as a result of the increased service and other revenues. The remainder of the increase was primarily due to the inclusion of a full quarter of Cytoc results in the current year as compared to 10 of the 13 weeks in the prior year quarter. The cost of service and other revenues as a percentage of service and other revenues in the first quarter of fiscal 2009 decreased to 76% from 94% in the prior year due in part to the improved absorption of fixed service costs and the continued growth of service contract revenue, primarily in the Breast Health segment.

Please see *Cost of Product Sales* above for discussion of the reclassification between *cost of product sales* and *cost of service and other revenues* during fiscal 2008.

Operating Expenses.

	Three Months Ended		Three Months Ended		Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Revenue	Amount	% of Total Revenue	Amount	%
<i>Operating Expenses</i>						
Research and Development	\$ 23,793	6%	\$ 20,147	5%	\$ 3,646	18%
Selling and Marketing	65,708	15%	56,986	15%	8,722	15%
General and Administrative	34,805	8%	34,334	9%	471	1%
Amortization of Acquired Intangibles	12,638	3%	6,249	2%	6,389	102%
Impairment of Acquired Intangibles		%	2,900	1%	(2,900)	(100)%
Charge for Acquired In-Process Research and Development		%	370,000	100%	(370,000)	(100)%
	\$ 136,944	32%	\$ 490,616	132%	\$ (353,672)	(72)%

Research and Development Expenses. Research and development expenses increased 18% in the current quarter as compared to the corresponding period in the prior year. This increase was primarily due to the inclusion of \$5.1 million of expenses in the first quarter of the current year associated with Third Wave-related activity as well as the inclusion of Cytoc-related activity for the full quarter in the current year as compared to 10 of the 13 weeks in the prior year quarter. These increases were partially offset by a decrease in related headcount, bonus and project-related expenses resulting from a number of cost reduction initiatives we implemented in the first quarter of 2009. In addition, the first quarter of fiscal 2008 included a \$1.8 million charge related to a change in control payment associated with the Cytoc business combination. We expect total research and development expenses to increase in the remainder of fiscal 2009 due to the timing of clinical trial expenses and costs related to the commercial release of new products.

Selling and Marketing Expenses. Selling and marketing expenses increased 15% in the current quarter as compared to the corresponding period in the prior year. This increase was primarily due to the inclusion of a full quarter of Cytoc-related activity in the current year as compared to 10 of the 13 weeks in the prior year quarter as well as approximately \$3.4 million of expenses in the first quarter of the current year from Third Wave-related activity, slightly offset by a decrease in commission-related expenses and other cost reductions resulting from our cost reduction initiatives implemented in the first quarter of 2009. We expect total sales and marketing expenses to decrease slightly in the remainder of fiscal 2009 as a result of our cost reduction initiatives.

General and Administrative Expenses. General and administrative expenses increased slightly in the current quarter compared to the corresponding period in the prior year primarily due to the inclusion of approximately \$2.9 million of expenses related to Third Wave-related

Edgar Filing: HOLOGIC INC - Form 10-Q

activity and a full quarter of Cytoc-related activity in the current year quarter as compared to 10 of the 13 weeks in the prior year quarter, partially offset by a decrease in stock-based compensation, reduction in headcount and other expenses resulting from our cost reduction initiatives. We expect total general and administrative expenses to increase slightly in the remainder of fiscal 2009.

Table of Contents

Amortization of Acquired Intangible Assets. Amortization of acquired intangible assets results from customer relationships and trade names related to our acquisitions. These intangible assets are generally being amortized over their estimated useful lives of between 8.5 and 30 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows. The increase in these costs primarily relates to additional Cytyc-related amortization based on the pattern of amortization in which the economic benefit is being consumed and amortization related to the Third Wave acquisition.

Impairment of Acquired Intangible Assets. Subsequent to the Cytyc business combination, we discontinued the development of Cytyc's Helica Thermal Coagulator System product, used for the treatment of endometriosis. We will not realize any future cash flows from this product. Our intangible asset valuation for Cytyc included approximately \$2.9 million related to customer relationships for Helica. As a result of the Helica product discontinuation, we recorded an impairment charge of \$2.9 million during the first quarter of fiscal 2008.

Acquired In-Process Research and Development Expenses. The \$370.0 million charge for in-process research and development in the first quarter of fiscal 2008 was incurred in connection with our business combination with Cytyc as described in further detail above under Valuation of Acquired In-Process Research and Development - Cytyc Merger.

Interest Income.

	Three Months Ended		Change	
	December 27, 2008	December 29, 2007	Amount	%
<i>Interest Income</i>	\$ 446	\$ 2,253	\$ (1,807)	(80)%

Interest income decreased 80% in the current quarter compared to the corresponding period in the prior year primarily due to a decrease in our investment balances as we utilize excess cash to repay our term loans and, to a lesser extent, a decrease in interest rates.

Interest Expense.

	Three Months Ended		Change	
	December 27, 2008	December 29, 2007	Amount	%
<i>Interest Expense</i>	\$ (18,410)	\$ (31,660)	\$ 13,250	42%

These expenses consisted primarily of the interest costs and the related amortization of deferred financing costs related to both the senior secured credit agreement entered into on October 22, 2007 in connection with the Cytyc business combination and amended on July 17, 2008 in connection with the Third Wave acquisition and our 2.0% Convertible Note Offering that was entered into in December 2007 and used to pay down a portion of the term loans, which had higher interest rates. The decrease in interest expense is caused in part by reduced term loan balances and lower interest rates on our outstanding term loan balances. Additionally, we had the benefit of the lower interest rates from our Convertible Note Offering for the full quarter in fiscal 2009 as compared to less than a month in the first quarter of fiscal 2008.

Other Expense, net.

	Three Months Ended		Change	
	December 27, 2008	December 29, 2007	Amount	%
<i>Other Expense, net</i>	\$ (3,081)	\$ (15)	\$ (3,066)	(20,440)%

In the current quarter, these expenses primarily included foreign currency transaction losses of approximately \$2.1 million and a decrease in the cash surrender value of life insurance contracts related to our SERP of approximately \$1.1 million. In the first quarter of fiscal 2008, these expenses were primarily related to a loss on disposal of property and equipment of \$57,000 partially offset by foreign currency transaction gains

Edgar Filing: HOLOGIC INC - Form 10-Q

of \$26,000. To the extent that foreign currency exchange rates fluctuate in the future, we may be exposed to continued financial risk. Although we have established certain debt agreements denominated in the foreign currency, the Euro, in which certain of our subsidiaries currently conduct business as well as other measures to minimize this risk, we cannot assure that we will be successful or can fully hedge our outstanding exposure.

Table of Contents**Provision for Income Taxes.**

	Three Months Ended		Change	
	December 27, 2008 Amount	December 29, 2007 Amount	Amount	%
<i>Provision for Income Taxes</i>	\$ 24,683	\$ 6,405	\$ 18,278	285%

We account for income taxes under SFAS No. 109, *Accounting for Income Taxes*. This statement requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. While we have considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance, in the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, an adjustment to the deferred tax asset would increase income in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our net deferred tax asset in the future, an adjustment to the deferred tax asset would be charged to income in the period such determination was made. Our effective tax rate was 34% of pre-tax earnings in the first quarter of fiscal 2009 and (1.8)% of the pre-tax loss in the first quarter of fiscal 2008. In the current quarter our effective tax rate was reduced primarily by the retroactive reinstatement of the Federal research and development tax credit. For the three months ended December 29, 2007, our effective tax rate was affected by the in-process research and development charge we incurred in connection with our business combination with Cytyc. We expect an effective tax rate of approximately 35%-36% of pre-tax earnings in fiscal 2009.

Segment Results of Operations

We report our business as four segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The accounting policies of the segments are the same as those described in the footnotes to the accompanying consolidated financial statements included in our 2008 Annual Report on Form 10-K. We measure segment performance based on total revenues and operating income or loss. Revenues from product sales of each of these segments are described in further detail above. The discussion that follows is a summary analysis of total revenues and the primary changes in operating income or loss by segment.

Breast Health.

	Three Months Ended		Change	
	December 27, 2008	December 29, 2007	Amount	%
	% of Total Segment Revenue	% of Total Segment Revenue		
Total Revenues	\$ 199,112	\$ 196,962	\$ 2,150	1%
Operating Income	\$ 44,960	\$ 42,672	\$ 2,288	5%

Breast Health revenues increased slightly due to a \$13.7 million increase in service revenues that was primarily related to additional service contracts for the increased number of Selenia systems in our installed base and a \$5.3 million increase in sales of our Suros breast biopsy products, partially offset by a \$13.2 million decrease in sales of Selenia full field mammography systems and related components as discussed above. Operating income for this business segment increased primarily due to the increased revenues, reduced product costs due to the \$2.5 million of additional costs related to sales of acquired MammoSite inventory that was written up to fair value for purchase accounting purposes in the first quarter of fiscal 2008 and reduced operating expenses resulting from decreased mammography-related research and development spending on our Dimensions tomosynthesis product as well as cost reduction initiatives implemented in the first quarter of 2009. Our gross margin in this business segment was 49% in the current quarter as compared to 50% in the first quarter of the prior year. The slight decrease in our gross margins in the current quarter was primarily caused by lower absorption of manufacturing costs due to lower volumes.

Table of Contents*Diagnostics.*

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Segment Revenue	Amount	% of Total Segment Revenue	Amount	%
Total Revenues	\$ 134,624	100%	\$ 100,312	100%	\$ 34,312	34%
Operating Income (Loss)	\$ 24,283	18%	\$ (81,970)	(82)%	\$ 106,253	130%

Diagnostics revenues, which include our ThinPrep, FullTerm and Third Wave products, totaled \$134.6 million in the first quarter of fiscal 2009 as compared to \$100.3 million in the first quarter of fiscal 2008. These revenues include both Cytoc and Third Wave results for the full quarter in fiscal 2009 of \$126.1 million and \$8.5 million, respectively. Revenue in the first quarter of fiscal 2008 includes only 10 out of 13 weeks of revenue from Cytoc, as the business combination took place on October 22, 2007. Our gross margin in this business segment increased to 56% in the current quarter from 36% in the first quarter of fiscal 2008. Our gross margins were reduced in the first quarters of 2009 and 2008 by charges for the write-up to fair value of inventory sold during those periods for Third Wave totaling \$0.6 million and for Cytoc totaling \$26.6 million, respectively. Also reducing gross margins in both periods is amortization of acquired intangible assets which totaled \$22.6 million and \$11.8 million in the first quarter of fiscal 2009 and 2008, respectively. Operating income in this segment increased in the current quarter as compared to the same period in the prior year due to the factors described above and an \$85.2 million charge for in-process research and development included in the prior year quarter, partially offset by a \$2.4 million increase in stock-based compensation in the current quarter.

GYN Surgical.

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Segment Revenue	Amount	% of Total Segment Revenue	Amount	%
Total Revenues	\$ 67,949	100%	\$ 49,886	100%	\$ 18,063	36%
Operating Income (Loss)	\$ 19,981	29%	\$ (282,872)	(567)%	\$ 302,853	107%

GYN Surgical revenues, which include our NovaSure products and Adiana systems under development, totaled \$67.9 million in the first quarter of fiscal 2009 as compared to \$49.9 million in the corresponding period in the prior year. The increase in revenues is primarily due to the inclusion of Cytoc-related activity for the full quarter in the current year as compared to 10 of the 13 weeks in the prior year quarter and an increase in the number of NovaSure systems sold in the current quarter. Our gross margin in this business segment increased to 69% in the current quarter from 54% in the first quarter of fiscal 2008, primarily due to a \$12.4 million charge for the write-up to fair value of inventory that was included in the prior year. Gross margins decreased in both periods due to amortization of acquired intangible assets which totaled \$9.6 million and \$3.9 million in the first quarter of fiscal 2009 and 2008, respectively. The operating loss for the first quarter of fiscal 2008 included a \$284.8 million charge for in-process research and development as a result of the Cytoc business combination and a \$2.9 million impairment charge of the Helica Thermal Coagulator System intangibles.

Skeletal Health.

	Three Months Ended				Change	
	December 27, 2008		December 29, 2007			
	Amount	% of Total Segment Revenue	Amount	% of Total Segment Revenue	Amount	%

Edgar Filing: HOLOGIC INC - Form 10-Q

Total Revenues	\$ 27,548	100%	\$ 24,285	100%	\$ 3,263	13%
Operating Income (Loss)	\$ 4,497	16%	\$ (611)	(3)%	\$ 5,108	836%

Skeletal Health revenues increased in the current quarter compared to the corresponding period in the prior year primarily due to the \$3.5 million increase in product sales discussed above. Our gross margin in this business segment was 41% in the current quarter as compared to 30% in the first quarter of the prior year. Operating income and gross margin for the Skeletal Health segment increased during this period primarily due to the increased revenues, improved absorption and reduced operating expenses, primarily resulting from cost reduction initiatives implemented in the first quarter of 2009. The operating loss and gross margin in the first quarter of fiscal 2008 for this segment included a \$2.0 million charge associated with MRI inventory. Skeletal Health costs and expenses included \$0.4 million and \$1.0 million of stock-based compensation in the first quarter of fiscal 2009 and 2008, respectively.

Table of Contents

Liquidity and Capital Resources

At December 27, 2008 we had approximately \$431.4 million of working capital. At that date our unrestricted cash and cash equivalents totaled \$171.5 million. Our unrestricted cash and cash equivalents balance increased by approximately \$75.8 million during the first quarter of fiscal 2009, primarily from cash generated from our operations. This cash source was partially offset by our financing activities relating to our repayment of amounts outstanding under our credit agreement, as well as cash used in our investing activities including cash used to purchase property and equipment.

Our operating activities provided us with \$120.9 million of cash, which included net income of \$48.0 million for the first quarter of fiscal 2009, increased by non-cash charges for depreciation and amortization of an aggregate \$66.2 million and stock-based compensation expense of \$7.5 million. Cash provided by operations due to changes in our current assets and liabilities included a decrease in income tax refundable of \$17.7 million, an increase in deferred revenue of \$9.4 million and a decrease in accounts receivable of \$5.3 million. The cash provided by these changes in our current assets and liabilities was offset by a decrease in accrued expenses of \$24.8 million, an increase in inventories of \$8.7 million, and a decrease in accounts payable of \$5.5 million. The decrease in income taxes refundable was due to the utilization of net operating loss carry forward amounts to offset current taxable income. The increase in deferred revenue was primarily due to an increase in the number of service contracts as our installed base continues to grow. The decrease in accounts receivable was primarily due to the decline in sales volume in the current quarter as compared to the fourth quarter of fiscal 2008. The decrease in accrued expenses was primarily due to the payment of accrued compensation, which included our annual bonus payment. The increase in inventories was primarily related to the increase in finished goods and related components on hand as a result of the decline in sales volume. The decrease in accounts payable was primarily due to the timing of payments.

In the first quarter of fiscal 2009, we used approximately \$17.5 million of cash in investing activities. This use of cash was primarily attributable to \$9.5 million for purchases of property and equipment, which consisted primarily of manufacturing, demonstration and test equipment and computer hardware. We also invested \$4.0 million in equipment under customer usage agreements. The \$3.1 million increase in other assets is primarily related to \$3.3 million of cash that was used to purchase certain life insurance contracts to fund future payments under our SERP.

In the first quarter of fiscal 2009, we utilized \$28.9 million of cash in financing activities, substantially for repayments of the term loans under our credit agreement.

Indebtedness

Credit Agreement.

On July 17, 2008, in connection with our acquisition of Third Wave, we entered into an amended and restated credit agreement (the *Amended Credit Agreement*) with Goldman Sachs Credit Partners L.P. and certain other lenders (collectively, the *Lenders*). The Amended Credit Agreement amended and restated our existing credit agreement with the Lenders, dated as of October 22, 2007.

Pursuant to the terms and conditions of the Amended Credit Agreement, the Lenders committed to provide senior secured financing in an aggregate amount of up to \$800 million. The credit facility consisted of \$400 million under a senior secured tranche A term loan (*Term Loan A*); \$200 million under a senior secured tranche B term loan (*Term Loan B*); and \$200 million under a senior secured revolving credit facility (the *Revolving Facility*).

In order to complete the acquisition of Third Wave, we initially borrowed \$540 million under the credit facilities on July 17, 2008, consisting of \$400 million under the Term Loan A and \$140 million under the Term Loan B. As of December 27, 2008, we had an aggregate of approximately \$436 million of principal outstanding under this credit facility of which approximately \$321 million was under the Term Loan A and approximately \$115 million was under the Term Loan B. The long-term portion of the Term Loan A and Term Loan B was \$288 million and \$113 million, respectively, at December 27, 2008.

Our domestic subsidiaries which are party to the Amended Credit Agreement (including Third Wave, which joined as a party to the agreement on July 24, 2008, the effective date of the transaction) have guaranteed our obligations under the credit facilities and the credit facilities are secured by first-priority liens on, and first-priority security interests in, substantially all of our assets, a first priority security interest in 100% of the capital stock issued by each guarantor, 65% of the capital stock issued by certain of our first-tier foreign subsidiaries and all intercompany debt. The security interests are evidenced by an Amended and Restated Pledge and Security Agreement by and among Goldman Sachs Credit Partners L.P., as collateral agent, us and the other parties therein named (the *Amended Pledge and Security Agreement*).

All amounts outstanding under the credit facilities will bear interest, at our option, as follows:

Edgar Filing: HOLOGIC INC - Form 10-Q

Initially, with respect to loans made under the revolving facility and the Term Loan A:

- (i) at the Base Rate plus 1.50% per annum; or
- (ii) at the reserve adjusted Eurodollar Rate plus 2.50% per annum; and

Table of Contents

With respect to loans made under the Term Loan B:

- (i) at the Base Rate plus 2.25% per annum; or
- (ii) at the reserve adjusted Eurodollar Rate plus 3.25% per annum.

The margin applicable to loans under the Revolving Facility and the Term Loan A is subject to specified changes based on certain changes in the leverage ratio as specified in the Amended Credit Agreement.

Interest accruing at the base rate generally is payable on a quarterly basis. Interest accruing at the Eurodollar Rate is payable on the last day of selected interest periods (which shall be one, two, three and six months and in certain circumstances, nine or twelve months) unless the interest period exceeds three months, in which case, interest will be due at the end of every three months. The weighted average interest rate under the Amended Credit Agreement was 5.24% during the first quarter of fiscal 2009.

We are required to pay a quarterly commitment fee, at a per annum rate of 0.50%, on the undrawn commitments available under the revolving credit facility, which per annum rate is subject to reduction based on a leverage ratio as specified in the Amended Credit Agreement.

The credit facilities contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including financial covenants which require us to maintain maximum leverage and minimum interest coverage ratios, as of the last day of each fiscal quarter. We were in compliance with our financial covenants as of December 27, 2008.

Convertible Notes. On December 10, 2007, we issued and sold \$1.725 billion aggregate original principal amount of our 2.00% Convertible Senior Notes due 2037. The notes were registered under an effective Registration Statement and were issued pursuant to an Indenture between us and Wilmington Trust Company, as Trustee and a First Supplemental Indenture thereto, both dated December 10, 2007.

The net proceeds from the offering was approximately \$1.69 billion, after deducting the underwriters' discounts and estimated offering expenses of approximately \$1.5 million payable by us, and was used to repay a portion of our then outstanding senior secured indebtedness under our Credit Agreement.

Holders may require us to repurchase the notes on December 13 of 2013, and on each of December 15, 2017, 2022, 2027 and 2032 at a repurchase price equal to 100% of their accreted principal amount, plus accrued and unpaid interest. We may redeem any of the notes beginning December 18, 2013, by giving holders at least 30 days' notice. We may redeem the notes either in whole or in part at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest, including contingent interest and liquidated damages, if any, to, but excluding, the redemption date.

The notes bear interest at a rate of 2.00% per year on the principal amount, payable semi-annually in arrears in cash on June 15 and December 15 of each year, beginning June 15, 2008, and ending on December 15, 2013 and will accrete principal from December 15, 2013 at a rate that provides holders with an aggregate annual yield to maturity of 2.00% per year. Beginning with the six month interest period commencing December 15, 2013, we will pay contingent interest during any six month interest period to the holders of notes if the trading price, as defined, of the notes for each of the five trading days ending on the second trading day immediately preceding the first day of the applicable six month interest period equals or exceeds 120% of the accreted principal amount of the notes.

The holders of the notes may convert the notes into shares of our common stock at a conversion price of approximately \$38.60 per share, subject to adjustment, prior to the close of business on September 15, 2037, subject to prior redemption or repurchase of the notes, upon the occurrence of certain events, as defined. None of the events that would allow the holders to convert prior to September 15, 2037 have occurred to date.

In lieu of delivery of shares of our common stock in satisfaction of our obligation upon conversion of the notes, we may elect to deliver cash or a combination of cash and shares of our common stock. If we elect to satisfy our conversion obligation in a combination of cash and shares of our common stock, we will deliver up to a specified dollar amount of cash per \$1,000 original principal amount of notes, and will settle the remainder of our conversion obligation in shares of our common stock, in each case based on the daily conversion value calculated as provided in the indenture for the notes. It is our current intent and policy to settle any conversion of the notes as if we had elected to make the net share settlement election.

The notes are our senior unsecured obligations and rank equally with all of our existing and future senior unsecured debt and prior to all future subordinated debt. The notes are effectively subordinated to any future secured indebtedness to the extent of the collateral securing such indebtedness, and structurally subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

Edgar Filing: HOLOGIC INC - Form 10-Q

AEG Debt. AEG has outstanding existing debt in aggregate principal amount of \$10.0 million as of December 27, 2008. The terms of the loans have various maturities ranging from December 30, 2010 through March 30, 2014. Interest rates are variable and average interest rates in the three months ended December 27, 2008 ranged from 3.9% to 4.3%.

Table of Contents

Financing Leases. Cytyc entered into a lease agreement on April 23, 2007 for a new manufacturing and office facility located in Alajuela, Costa Rica. The lease term commenced in May 2008 and we expect to transfer most of our Costa Rican operations to this facility by the end of the second quarter of fiscal 2009. The term of the lease is for a period of approximately ten years with the option to extend for two consecutive five-year terms.

On July 11, 2006, Cytyc entered into a lease agreement for a manufacturing facility located in Marlborough, Massachusetts. The term of the lease is for a period of approximately 12 years commencing on November 14, 2006. In 2011, we will have an option to lease an additional 30,000 square feet. In connection with our merger with Cytyc, we guaranteed Cytyc's obligations under this lease.

Other Indebtedness. As a result of the Cytyc merger, we assumed Cytyc's outstanding convertible notes, of which \$0.3 million remained outstanding as of December 27, 2008. We may redeem these notes at par at any time on or after March 20, 2009. The stated interest rate is fixed at 2.25%.

Contingent Earn-Out Payments

As a result of the Cytyc merger, we assumed Cytyc's obligation to Adiana, Inc. to make contingent earn-out payments tied to the achievement of milestones. The milestone payments include potential contingent payments of up to \$155 million, based on the achievement of certain FDA milestones and on incremental sales growth of the Adiana permanent contraception product during the four-year period following FDA approval of this product.

We have satisfied our obligation for a second and final earn-out to the former Suros Surgical stockholders related to Suros' incremental revenue growth for revenues earned through July 31, 2008. We accrued an amount of approximately \$24.5 million for this second annual earn-out in the fourth quarter of 2008, with an increase to goodwill, which was paid in full as of December 27, 2008. We had also made a payment of approximately \$19.0 million to the former Suros stockholders in the fourth quarter of fiscal 2007 for the first year earn-out.

We also have an obligation for up to two annual earn-out payments not to exceed \$15.0 million in the aggregate based on BioLucent's achievement of certain revenue targets. We have considered the provisions of Emerging Issues Task Force (EITF) Issue No. 95-8, *Accounting for Contingent Consideration Paid to the Shareholders of an Acquired Enterprise in a Purchase Business Combination*, and concluded that this contingent consideration will represent additional purchase price. As a result, goodwill will be increased by the amount of the additional consideration, if any, when it becomes due and payable. As of December 27, 2008, the revenue targets have not been achieved and we have not recorded any amounts for these potential earn-outs.

Recent Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141 (Revised 2007), *Business Combinations* (SFAS 141(R)). This Statement retains the fundamental requirements in SFAS 141 that the acquisition method of accounting (which SFAS 141 called the purchase method) be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) requires an acquirer to recognize the assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the Statement. That replaces SFAS 141's cost-allocation process, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair values. The Statement retains the guidance in SFAS 141 for identifying and recognizing intangible assets separately from goodwill. SFAS 141(R) will now require acquisition costs to be expensed as incurred, restructuring costs associated with a business combination must generally be expensed prior to the acquisition date and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense. SFAS 141 applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, which is our 2010 fiscal year. Earlier adoption is prohibited.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements - An amendment of ARB No. 51* (SFAS 160). SFAS 160 amends Accounting Research Bulletin No. 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements.

The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement. SFAS 160 clarifies that changes in a parent's ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this Statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, which is our 2010 fiscal year. Earlier adoption is prohibited.

Edgar Filing: HOLOGIC INC - Form 10-Q

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS 161), which amends SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities* (SFAS 133), by requiring expanded disclosures about an entity's derivative instruments and hedging activities. SFAS 161 requires increased qualitative, quantitative, and credit-risk disclosures, including (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations, and (c) how derivative

Table of Contents

instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. We are required to adopt SFAS 161 effective for the quarter ended March 28, 2009. Since SFAS 161 requires only additional disclosures concerning derivatives and hedging activities, its adoption will not affect our financial condition, results of operations or cash flows.

In April 2008, the FASB issued FASB Staff Position (FSP) No. 142-3, *Determination of the Useful Life of Intangible Assets*, which amends the factors that must be considered in developing renewal or extension assumptions used to determine the useful life over which to amortize the cost of a recognized intangible asset under SFAS 142. The objective of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS 141(R). The FSP is effective for financial statements for fiscal years beginning after December 15, 2008, which will be our fiscal 2010. Early adoption is prohibited.

In May 2008, the FASB issued FSP No. APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)* (FSP APB 14-1). This FSP applies to convertible debt instruments that, by their stated terms, may be settled in cash (or other assets) upon conversion, including partial cash settlement, unless the embedded conversion option is required to be separately accounted for as a derivative under SFAS 133. The liability and equity components of convertible debt instruments within the scope of this FSP must be separately accounted for in a manner that will reflect the entity's nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. The excess of the principal amount of the debt over the amount ultimately allocated to the liability component is required to be amortized to interest expense using the interest method. This FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. As a result, we will adopt this standard at the beginning of fiscal 2010. This FSP must be applied retrospectively to all periods presented. The retrospective adoption of this FSP will increase our historical reported interest expense from December 10, 2007 (issuance date of the Convertible Notes) forward.

The adoption of FSP APB 14-1 will have no impact on our actual past or future cash flows. However, upon adoption in fiscal 2010 we will restate prior periods by reclassifying approximately \$470.0 million of our Convertible Notes to additional paid-in capital, resulting in a debt discount. It is estimated that our non-cash interest expense will increase by approximately \$2.6 million for the three months ended December 29, 2007 and approximately \$15.9 million for the three months ended December 27, 2008, resulting in a restated diluted net loss per share of approximately \$1.66 for the three months ended December 29, 2007 and restated diluted net income per share of approximately \$0.15 for the three months ended December 27, 2008.

In June 2008, the FASB ratified the consensus reached on EITF Issue No. 07-05, *Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock* (EITF 07-05). EITF 07-05 clarifies the determination of whether an instrument (or an embedded feature) is indexed to an entity's own stock, which would qualify as a scope exception under SFAS 133. EITF 07-05 is effective for financial statements issued for fiscal years beginning after December 15, 2008. Early adoption for an existing instrument is not permitted. We are currently evaluating the impact that the adoption of EITF 07-05 will have on our consolidated financial statements.

Table of Contents
Item 3. Quantitative and Qualitative Disclosure About Market Risk.

Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments. SFAS No. 107, *Disclosure of Fair Value of Financial Instruments*, requires disclosure about fair value of financial instruments. Financial instruments consist of cash equivalents, accounts receivable, cost method investments and debt obligations. Except for our outstanding convertible notes, the fair value of these financial instruments approximates their carrying amount. As of December 27, 2008 we have \$1.725 billion of Convertible Notes outstanding. The fair value of our Convertible Notes was approximately \$992 million as of December 27, 2008 based on the trading price as of that date.

Primary Market Risk Exposures. Our primary market risk exposures are in the areas of interest rate risk and foreign currency exchange rate risk. We incur interest expense on borrowings outstanding under our Amended Credit Agreement and on the debt assumed as a result of our acquisition of AEG. Borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to, at our option, with respect to the borrowings under the Revolving Facility and Term Loan A of either (1) the Base Rate (the greater of the prime rate as quoted in *The Wall Street Journal* and the Federal Funds Effective Rate) plus 1.5% or (2) the Eurodollar Rate, plus 2.5% and with respect to the Term Loan B of either (1) the Base Rate (the greater of the prime rate as quoted in *The Wall Street Journal* and the Federal Funds Effective Rate) plus 2.25% or (2) the Eurodollar Rate, plus 3.25%.

On July 17, 2008, the date we entered into the Amended Credit Agreement, we borrowed \$400 million under the Term Loan A and \$140 million under the Term Loan B. As of December 27, 2008, there was approximately \$436 million outstanding under the Amended Credit Agreement, including \$321 million under the Term Loan A facility which matures on September 30, 2012 and \$115 million under the Term Loan B facility which matures on March 31, 2013.

The terms of the AEG debt agreements have various maturities ranging from December 30, 2010 through March 30, 2014. Interest rates are variable and had average interest rates ranging from 3.9% to 4.3% during the three months ended December 27, 2008. We may also incur interest expense on loans made under a European line of credit that accrues interest at the Europe Interbank Offered Rate 7.5%, as defined. At December 27, 2008, there were no amounts outstanding under the European line of credit.

These debt obligations are variable rate instruments and our interest expense associated with these instruments is, therefore, subject to changes in market interest rates. A 10% adverse movement (increase in LIBOR) would not have a material adverse effect on our financial condition.

The return from cash and cash equivalents will vary as short-term interest rates change. A hypothetical 10% increase or decrease in interest rates, however, would not have a material adverse effect on our financial condition. Interest income on our cash and cash equivalents is recorded as a component of Other Income in our accompanying Consolidated Statements of Operations.

Foreign Currency Exchange Risk. Our international business is subject to risks, including, but not limited to: unique economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. Accordingly, our future results could be materially adversely impacted by changes in these or other factors.

We maintain sales and service offices outside the United States, have manufacturing facilities in Germany, Costa Rica and China, and conduct business worldwide. The expenses of our international offices are denominated in local currencies, except at our Costa Rica subsidiary, where the majority of the business is conducted in U.S. dollars. Our foreign sales are denominated in local currencies, the Euro or U.S. dollars. Fluctuations in the foreign currency rates could affect our cost of goods and operating margins and could result in exchange losses. In addition, currency devaluations can result in a loss if we hold deposits of that currency.

We believe that the operating expenses of our international subsidiaries that are incurred in local currencies will not have a material adverse effect on our business, results of operations or financial condition. Our operating results and certain assets and liabilities that are denominated in the Euro are affected by changes in the relative strength of the U.S. dollar against the Euro. Our expenses are positively affected when the U.S. dollar strengthens against the Euro and adversely affected when the U.S. dollar weakens. However, we believe that the foreign currency exchange risk is not significant.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if forced to sell securities that experience a decline in market value due to changes in interest rates. A hypothetical 10% increase or decrease in interest rates, however, would not have a material adverse effect on our financial condition. Interest income on our investments is recorded as a component of Other Income in our accompanying Consolidated Statements of Operations.

Table of Contents

Item 4. Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As of December 27, 2008, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.

Table of Contents

PART II OTHER INFORMATION

HOLOGIC, INC.

Item 1. Legal Proceedings.

There are no material changes in Legal Proceedings as previously disclosed in our Annual Report on Form 10-K for our fiscal year ended September 27, 2008.

Item 1A. Risk Factors

There are no material changes in the risk factors as previously disclosed in our Annual Report on Form 10-K for our fiscal year ended September 27, 2008 except as set forth below:

Based upon a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of our market capitalization below the book value of our net assets, we concluded that potential goodwill impairment indicators existed as of December 27, 2008 that could require us to incur an impairment charge in the second quarter of fiscal 2009 that would have a material adverse impact on our operating results.

We periodically review the carrying value of the goodwill and other long-lived assets reflected in our financial statements to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment of the value of these assets. Based upon a combination of factors, including the deteriorating macro-economic environment, declines in the stock market and the decline of our market capitalization significantly below the book value of our net assets, we concluded that potential goodwill impairment indicators existed as of December 27, 2008. As a result, we are performing an interim goodwill impairment analysis as of December 27, 2008. Step 1 of our impairment analysis indicates that the carrying value of the net assets of certain reporting units, primarily acquired in connection with the Cytoc acquisition, exceeds the estimated fair value of those reporting units. These reporting units had goodwill totaling approximately \$4.0 billion, as of December 27, 2008. As a result, we will be required to perform Step 2 of the goodwill impairment test to determine the amount, if any, of goodwill impairment charges by reporting unit to be recorded by us. We expect to complete the Step 2 analysis by the end of our fiscal second quarter, March 28, 2009. In the event that we determine that our goodwill is impaired in whole or in part, we will record an impairment charge in the second quarter of fiscal 2009, which could have a material adverse impact our operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information.

None.

Table of Contents**Item 6. Exhibits**

(a) Exhibits

Exhibit Number		Reference
3.1	Second Amended and Restated By-laws of Hologic, Inc., as amended (filed as Exhibit 3.1 to Hologic's Current Report on Form 8-K filed with the SEC on December 12, 2008 and incorporated herein by reference).	
10.1	Form of Independent Director Stock Option Award Agreement (filed as Exhibit 10.1 to Hologic's Current Report on Form 8-K filed with the SEC on December 12, 2008 and incorporated herein by reference).	
10.2	Form of Independent Director Restricted Stock Unit Award Agreement (filed as Exhibit 10.2 to Hologic's Current Report on Form 8-K filed with the SEC on December 12, 2008 and incorporated herein by reference).	
10.3	Amendment No. 3 to Second Amended and Restated 1999 Equity Incentive Plan (filed as Exhibit 10.3 to Hologic's Current Report on Form 8-K filed with the SEC on December 12, 2008 and incorporated herein by reference).	
10.4	Amended and Restated Supplemental Executive Retirement Plan.	filed herewith
10.5	Form of Senior Vice President Change of Control Agreement including list of officers to whom provided.	filed herewith
31.1	Certification of Hologic's CEO pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	filed herewith
31.2	Certification of Hologic's CFO pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	filed herewith
32.1	Certification of Hologic's CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	filed herewith
32.2	Certification of Hologic's CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	filed herewith

Table of Contents

HOLOGIC, INC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Hologic, Inc.
(Registrant)

February 5, 2009
Date

/s/ JOHN W. CUMMING
John W. Cumming
Chief Executive Officer

February 5, 2009
Date

/s/ GLENN P. MUIR
Glenn P. Muir
Executive Vice President, Finance and Administration,
Treasurer and Assistant Secretary

(Principal Financial Officer)